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( ABSTRACT 
Studies of doxorubicin pharmacokinetics have been 
bedeviled by the problems 0£ low assay specificity and the 
possible degradation of doxorubicin and its netatolites 
during extraction. The purpose of this investigaticn was 
to provide a sensitive, selective, efficient and 
reproducible 
metabolites. 
assay method for doxorubicin and its 
A C-18 reversed phase HPLC method was chosen to 
analyze the drug concentrations and the Sep-pak cartridges 
were used for sample preparation. lhe Se~-pak cartridge 
retained doxorubicin and its metabolites while interfering 
compounds (e.g., protein, cellular compcnents) in the 
biological samples were eluted. Doxorubicin and its 
metabolites were then eluted with an acid-methanol mixture 
and concentrated in a water bath of 40° c. While plasma 
samples required no prior treatment befcre extraction, 
tissue samples were homogenized and released from binding 
to nuclear components by silver nitrate. lhe superiority 
of the Sep-pak method in sample preparation was estatlished 
by comparing 
the ease of 
the efficiency, accuracy, processing time and 
operation with the conventional crganic 
ii 
iii 
extraction method. 
ihe application of the assay method was tested in the 
plasma samples of human and rats, and tissue samples from 
rats. The results all showed a small variation and good 
agreement with the literature data. Pharmacokinetic 
profiles of these plasma samples were analyzed by AUTOAN 
and showed good correlation with those of literature and 
with each other. Plasma and kidney samples of the very 
young (2 months old) and the very old (2 years old) rats 
were analyzed but failed to observe any significant effect 
of age on doxoruticin pharmacokinetics. 
During the development of the assay methcd, it was 
necessary to perform a study of doxorubicin stability to 
ascertain the best conditions for drug analysis. 
Doxorubicin showed to be more stable in acidic medium and 
the effects of pH have been guantified. Its stability in 
solution could also be influenced by the ~offering agents 
used. The study of doxorubicin stability in plasma 
revealed that frozen plasma samples remained stable for 1 
month and the thawing/freezing of these samples should te 
avoided. 
Binding data obtained from the ultrafiltration method 
were unable to analyze due to high degree of tinding to the 
( 
iv 
Dia£16 membranes. lhis memtrane binding ~Laferty of 
doxorubicin not only caused an inconsistency amcng refeated 
experiments but also failed to provide an otservation of 
the fraction bound However, an ultracentrifugation method 
was performed and revealed that 0.7 fraction of doxoruticin 
was bound to 4 % albumin solution. 
This study clearly demonstrated tbat the 
the Sep-pak method and the reversed phase 
CCUfling of 
EPLC system 
frovided an efficient, sensitive, reproducible and accurate 
method for the pharmacokinetic studies of dcxcruticin. 
This new method was also much easier to use tban the 
organic extraction method. The stability studies indicated 
the suitable storage conditions for both plasma samples and 
doxorubicin solution during analysis. The binding data of 
0.7 fraction bound of total doxorubicin was frovided for 
future Fharmacokinetic studies. 
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( I. INTBODUCllON 
A. The Clinical Significance of Doxoruticin 
Cancer, perhaps the most feared of all diseases, has 
climbed to the second leading cause of death since 1976 
(1). Study regarding the chemctherapy of cancer and the 
disease itself has teen under extensive and vigcrous 
investigaticn. Numerous chemical 
developed by prodigious ef£orts of 
agents have been 
more than a decade. 
Clinical results have demonstrated that the use of these 
agents has produced a significant cure rate of various 
neoplasms, particularly the rapidly proliferating cancers 
of childhocd (2). 
Unfortunately, most antineoplastic agents possess a 
therapeutic index that is virtuaily one, i.e., at an 
effective therapeutic 
observed. Among the 
marrow and toxicities 
level, 
toxic 
toward 
toxic effects are also 
symtoms, de~ressicn of bone 
gastrointestinal tract and 
mucous membrane are cbserved with the application of almost 
·all the anticancer drugs (3). Another feature of these 
agents is the schedule-dependency which is the result of 
their effectiveness during certain phases of the cell cycle 
(4). Since active single agents are t~e requisite building 
block for a successful comtined chemotherapy strategy, a 
thorough understanding 
pharmacokinetics of these 
safe and eff€ctive use. 
of the 
agents 
2 
pharmacclcgy and 
is imperative for their 
Doxorulicin was discovered by Arcamore et al. in 1969 
and its chemical structure is shewn in Fig. 1. Jt is 
produced by a mutant strain of ~treptcm1ceE fEucetius 
(caesius variety), a microorganism that produces the 
closely rElated antibiotic, daunorubicin (also known as 
rubidomycin or ru.l:omycin) (fig. 1) (5). The attention 
focused on doxorubicin is 
against a broad spectrum 
to its efficacy mainly due· 
of tumors while its parent 
principally to tDe 
leukemia (E-10). In a 
by the National 
compound, daunoruticin, is confined 
treatment of acute nonlymphocytic 
report of cancer therapy protocols 
Institution of Health in 1981, doxorubicin was employed in 
almost 40% of 1106 clinical prctocols (11). With 
consideration of the progress in countries ether than 
United States, it is imfossible to overestimate the size of 
the ongoing clinical research cf doxorubicin (1~). 
lhe clinical usefulness of doxorubicin in l:reast 
cancer, pediatric solid tumors, csteosarccma, soft ~issue 
sarcoma, Hodgkin's and other malignant lymphoma attest~ to 
an unprecedented selectivity for cytotoxicity of neoplastic 
1.a 
OH 0 
0 OH 
·---o 
l. b 
•· I 
I 
I 
I 
I 
0 
II 
CCH3 
·.,OH 
Figure 1. The chemical structure of doxorubicin (1.a) and 
daunorubicin (1.b) 
3 
( 
4 
cells (13). However, normal cells are not exempt from 
their toxic actions. Toxic effects such as alopecia, 
nausea, stomatitis and hone marrow depressicn, ccmmon in 
most antinecplastic agents, are generally manageable and 
reversible. However, a freguent irreversible and often 
fatal congestive heart failure, a dose and schedule related 
consequence of treatment, seriously restricts the clinical 
usefulness cf doxorubicin (6-10,13,14). Although studies 
have supported the intravaneous administration by an 
intermittant single bolus dose and a cumulative dcse of 
less than 550 mg/m.& is generally considered safe 
(10,13,14). These guidelines, based on statistical rather 
than pathophysiolcgical and pharmacokinetic principles, 
often lead to underultilization of doxorubicin (14). Tc 
opti~ize the therapeutic tenefits of doxorubicin, study of 
its pharmacology, toxicities and pharmacokinetics should te 
further engaged. 
5 
B. An Assay Method for Pharmacokinetic Studies 
Although doxoruticin has been under investigation · for 
more than 10 years, a detailed and accurate pharmacokinetic 
model is not yet developed. It would be advantageous to 
ascertain which parameter or parameters are related to the 
~harmacological activity of doxoruticin, and most 
importantly, which parameter is pertinent to the hazardous 
cardiotoxicity. 
Early studies have suggested extensive accumulation of 
doxorubicin in several tissues and a slow and variable 
clearance (15,16). Clinical studies have clearly indicated 
a dose reduction in ~atients with either hepatic failure or 
a history of cardiac complications (16). it is only 
raticnal that a detailed understanding of the 
pharmacokinetic ~refile of doxorubicin is needed to 
determine the dose and schedule of administration to 
~atients on an individual basis. Since doxorulicinol (the 
major metabolite) possesses antitumor activity and the 
possible involvement of aglycones in cytotoxicity, it would 
be sensible to include these metabolites in this kinetic 
study. lhe relationship 
metabolites is depicted 
between doxoruticin and its 
in the tiotransformation ~athway 
shown in Fig. 2. Due to tbe fact that consideratle amount 
of doxorubicin is not recovered from excreta and cannot be 
0 OH 0 
II 
CCH20H 
.. OH 
CH30 0 ~ OH 
NH2 
I. doxorubicin 
0 OH OH I 
CHCH20H 
··oH 
IV. demethyldeoxydoxorubicinone 
l OH 0 OH I I 
CHCH20H 
... OH 
HS030 0 OH 
V. demethyldeoxyrub i cinone -
4 - 0-sulfate 
6 
0 OH 
0 OH ~H 
II. doxorubicinol NH2 · 
l 
III. doxorubicinone 
0 OH 
];;~~ 
H~ 
0 OH 
OH 
VI. demethyldeoxyrubicinone-
4-0 -B- glucuronide 
Figure 2. The proposed biotransformation pathway of doxorubicin 
( 
( 
accounted fer, it 
metabolites may 
has been 
be stored 
i;roposed that 
in the body 
search of such compounds is encouraged. 
1. The Pro.tlem 
Confusion over the pharmacokinetic 
some 
(17-19) 
7 
unknown 
and the 
studies of 
doxorubicin arises mainly from 
methcds. The total fluorescence 
tbe drawbacks of assay 
and the radiolabeled 
methods have shown nc si:ecificity, i.e., they are unatle tc 
differentiate doxoru.ticin and its metabclites (20-22). 
Additionally, it is reported that total plasma extractable 
fluorescence may be elevated due to the presence of certain 
steroids of bile acids causing interference, particularly 
at low drug levels (23). 
RIA (radioimmunoassay) and GLC-mass spectrometry have 
demonstrated high specificity and sensitivity. Hcwever, 
they are exfensive, time-consu~ing tc use and GLC requires 
derivatizaticn of the samples (24-27). At present, 1LC and 
HPLC are the twc methods generally used; this is partly 
due to the low cost of the procedures and the availability 
of instruments. 
Quantitative TLC analyses are usually hampered by 
various problems such as non-uLiform plate thickLess, 
8 
( difference in coating consistency, low sensitivity in 
detection and reproducibility (28) - Although recent 
advances in methodology have improved these deficiencies 
(29,30), a standard graph must be prepared for each plate 
run together with the samples (31,32). In addition to 
these sensitive variables that influence reprcducitility 
greatly, TLC method is accompanied with the falsely high 
levels of doxorubicinol (33) • Reich .§! _g_h (1979) 
identified artifactual metabolites that ccchrcmatographed 
in authentic doxorubicin and aglycones bands on 1LC plates, 
and they contributed 8 to 15 % to the metabolites levels 
(33). Isreal et _gl. (1978) performed a metabolism and 
excreticn study with both HPIC and TLC methods, and found 
( 
\ 
that at least one artifactual «etatolite was seen cnly on 
1LC plates (30) • Similar finding was identified by 
Benjamin g_t gl~ (1973), and they showed that the artifacts 
contributed 20% cf the total fluorescence of extracted 
samples (15). ~herefore, TIC method is considered an 
unreliable method unless care is taken to deal with these 
variable and artifactual metabolites levels. 
Due to its flexibility and reproducibility, HPIC has 
become the optimal method for the analysis of many drugs; 
such as penicillin, cephalosporins and tetracyclines (34). 
As doxorubicin "is c~ncerned, HPLC is considered the method 
of choice owing to its low volatility and stability. 
( 
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Various conditions have been developed and all have 
satisfactory specificity and sensitivity (24). Eowever, 
reversed-phase chromatography is considered i:articularly 
suitable for the separation of a homologous series of 
compounds, as in this study, doxorubicin and its 
metabolites, whose chemical structure may differ one from 
another by only one functional group. In addition, this 
type of HPLC system elates samples in reversed order of 
polarity which makes the detection of metatolites easier. 
A fluorescence detector is used in this study since it is 
more specific and sensitive than either u.v. or visitle 
spectrophotometry (35). 
As sami;les for i;harmacokinetic studies are of 
biological origin, extraction tecomes a necessity tc 
eliminate the possitle interference cf comi:cnents in 
biological fluids to compounds of interest (doxorubicin and 
its metabolites) and to chromatographic system. It is rare 
that samples do not reguire processing to i;:revent drugs 
binding to cellular components and to protect column 
packing and the detector of the H.Pl.C system. '.Ibis is 
usually done by homogenizing and extracting. 'I.be ordinary 
procedure for extraction is the conventional organic 
solvent extraction. Various organic solvents have been 
used with recovery rates of plasma sampies rariging from 70 
~ to 100 ~ (31,36-40). 
( 
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Better recoveries from plasma samples were seen mcstly 
with cosolvent extraction, such as chloroform-methanol and 
chlorof orm-isopropanol mixtures or with acidified ethanol 
extraction. Although Ekstorg (1978) has demonstrated, with 
chloroform-pentanol (9:1, v/v) mixture, that optimum 
extraction cccurs around pH 8.3 for doxorubicin, pE 8.6 for 
doxorubicinol, and pH 8.0 for daunorubicin (41). Acidified 
ethanol (by hydrochloric acid of different strengths) 
showed ~ recovery rate of 85%, but the possible degradation 
by hydrolysis of the glycosidic bond and high fluorescence 
blank should be heeded (15,42,43). The other cosolvent 
extraction methods usually couple with alkalinizing the 
aqueous phase either by a buffer or sodium hydroxide 
solution (17,37,38,44,45). ~he recovery rates cculd reach 
as high as 100 %. However, variation caused by 
experimental conditions seems great since different values, 
80, 84, 100 % of recovery were reported using the same 
method (17,44,45). 
Successful application of this pH adjusted solvent 
extraction method to tissues and cells is seen in a smaller 
frequency, some even reported as low 
spiked amount is recovered (42,46). 
as 40 and 60 % of 
lhis loss of 
doxorubicin and its metabolites is attributed to the slow 
release of these compounds from cellular ccmpcnents (39) • 
The strong and rapid binding ability of doxoruticin to DNA 
( 
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has shewn the associaticn constant to be in tne range of 
b 0.37 to 11.61x10 M in~~ vitr~ experiments (47). 
Schwartz (1973) demonstrated the capability of silver 
ions to release doxorubicin and daunorubicin from tinding 
to DNA. Silver ions also precipitate protein, flavines and 
nucleotides, therefore consideiably lower the fluoreEcence 
background (39) • The employment of silver nitrite 
increased the recovery rate from 26 % to 100 ~ for 
doxorubicin, and from 55 % to 104 % for daunoruticin (39). 
The conventional solvent e.xtrac ti on method, however 
efficient, is a teadious method which requires adjusting 
pH, mixing, separating phases, and sometimeE a Eecond even 
a third extraction is needed. The development cf a simpler 
method for extracticn is one of the objectives of this 
study. 
2. lheoretical Framework in Chromatography 
HPLC (high ~ressure liguid chromatography) is a 
separation technique and in which guantitation, 
reproducibility and simplicity are made possible by the 
technical advancement in instrumentation. Chromatography 
is defined as a separation process that is achieved by 
exploiting the different intermolecular force~ that are 
exerted on solutes when distrituted between a motile and 
( 
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stationary phases. Those substances that are held more 
strongly in mcbile phase pass through or from the system 
more rapidly than those that are held more strongly in the 
stationary phase. Thus, substances will mcve througn or 
from the system in order of increasing forces that bold 
them in the staticnary ~hase (48). 
Although the separation process is exceedingly 
complex, it is ~ossible to devise simple models and 
equations which closely approximate the separation. An 
understanding of these simple equations or relaticnshi~s is 
essential when i~provement of separation is needed. The 
ultimate goal of separation in HPIC is the achievement of 
the optimum combination of resolution of solutes, speed of 
elution, and economic use of pressure. In order to 
understand the relationship among these parameters, there 
are some fundamental terms that should be defined first 
(48,49) -
dead time; void time; t 0 : the time that requires 
for an unretainable solute to be eluted from a 
column 
dead volume; void volume; 
that requires for an 
eluted from a cclumn 
V0 : the volume of eluent 
unretainable solute to te 
13 
/ retention time; t~: the time that ela~se tetween 
injection and elution of a solute 
retention volume; v : the volume cf eluent that 
passes into the column during retention time 
peak width; W; the width of a peak at the taseline 
on a chromatogram 
capacity factor; k •• 
• 
k ' 
separation factor; selectivity; ~ ; 
ex == 
theoretical plates; N; 
N 
resolution; B; R5 ; 
R 
o r R H 0< - 1) ( k ' 
IX N 1 + k ' 
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The capacity factor, k', is a measure of the 
degree of retention of a solute. If value of k' is higher 
than 8, this means the system wastes valuable analytical 
time. Value of k' smaller than 1 is also unfavoratle due 
to potential interferences from nonretained peaks and early 
peaks of little or no analytical interest ( 49) - 1he 
separation factor, ~, is the net retenticn tixe ratio for 
two components. Fundamentally, ~ is equal to the ratio of 
equilibrium distributicn coefficient, which depends solely 
on the molecular forces between the solute a£d the two 
phases, i.e., the mobile and stationary phases. N is the 
number of theoretical plates in plate theory and whose 
higher value means better separation and efficiency. For a 
good column, N should be in the reascna£le range of 1,000 
and 20,000 (50). Resolution, E, is simply a means of 
measuring the degree of separation o( two compounds in a 
HPLC system. And resolution can te EXFressed in an 
equation which is the combination of selectivity (~), 
efficiency (N) and capacity (k') of a column. lhis version 
emphasizes three qualitative requirements for a good 
resolution; ( 1) solutes must be retained tc different 
extents, i.e., e< ~ 1; (2) solutes must .te retained, i.e., 
k' ~ O· 
• 
( 3) the column must be equivalent to a minimum 
number of theoretical plates (N) (4 8-50). 
These parameters, k •, e< , N, B, are the guidelines to 
15 
( judge whether a HPLC system is satisfactory or not. 
Improvement for the separation should le resolved from the 
tasic Van Deemter eguation which explains how factors in 
stationary and mobile phases influence the efficiency of a 
HPLC system (48, 49) • However, successful separations can 
be carried out only by careful experimentation preceded by 
shrewd planning. 
Among the various modes of HPLC (IL, LS, G.PC) , 
reversed-phase chromatography has some distinct advantages 
as it is less likely to be deactivated, can efficiently 
separate toth polar and ionic molecules, and it provides 
more freedom in choice of eluents. ~hese advantages also 
( 
act as a bonus in ~harmacokinetic studies since highly 
polar materials are present in tody fluids. Another 
advantage is the elution of solutes in reverse order of 
polarity which makes the detection of metabolites, usually 
polar than the parent compound, much easier. Eesides, the 
handling of aqueous motile phase is less hazardcus than the 
organic one (48-50). However, commercially available 
reversed stationary phase sometimes may exhitit lower 
efficiency and lower loading capacities than their parent 
silica gel substrates ( 48) • It is of interest to see 
whether the application of doxorubicin analysis in l:otb 
reversed-phase and normal phase liguid chromatographies 
shows any gualitative and guantitative differences. If no 
( 
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significant difference is detected in this study, 
reversed-phase HPIC stands as a favorable chioce for the 
pharmacckinetic study of doxorubicin. 
17 
( c. Stal:ility Study 
1. Purpose of This Study 
Several fluorometric procedures for the analysis of 
doxorubicin have been reported (31,36-40), tut little 
attention is given to its stability. It is very important 
to avoid artifacts caused by degradaticn fLior to the 
quantitative determination of doxorul::icin and its 
metal:olites. 
The sclid products, either as doxorul:icin 
hydrochloride salt er as a lyophilized Diixture of 
doxorubicin hydrochl~ride and lactose, are stal:le if stored 
in dry and well closed containers at room temperature (51). 
The stability of aqueous solution of doxorul::Jcin varies 
with temferature~ pH and buffering agents (24,51). 
However, this study exam~nes the effects of fH on tbe 
stability of doxorubicin since only one luf fer system is 
used and the experimental conditions seldom suffer any 
drastic change of tempeLature in the whole process. 
The same attention should be given to the handling of 
l:iological samples. ~hole blood, owing to the enzymes it 
contains, exhibits metatolic activity toward doxorubicin. 
The flasma doxorubicin concentration of whcle tlcod samples 
18 
decreased drastically during the first hour of incutation 
at 37°C (52). ihis effect is protatly due to the cellular 
uptake of doxorubicin, as no detectable amounts of 
doxorubicinol appeared in the plasma fraction during this 
peroid of time. Small amount of doxorubicinel did a~~ear 
in the plasma fraction when the whole blood sam~les had 
teen incubated fer mere than 1 hour (52). ln order to 
correlate the plasma levels with the concentrations of drug 
and metabolites in the circulating blood ~ithin the 
patients, reduction of this metabolic activity is 
desirable. 
Formation of metabolites ~as reduced ty storing the 
blood samples at lower temperature (4°C), by the addition 
of glutamate dehydrogenase or sonication (53). 1bouqb 
immediate sonication after the withdrawal of tlood samples 
from patients has been suggested (53), it has teen shown 
that poor recovery (70 %) resulted £rem this treatment 
{52). Since doxorubicin is not metabolized in cell-free 
~lasma samples (54) , the recommended procedure is immediate 
cooling of blood samples after withdrawal from ~atients and 
plasma fractions separated within 6 hours (52). 
Though the usual procedure for handling ~lasma and 
tissues is to immediately deep freeze the samples until 
analysis (31,36-40), it ha~ teen demonstrated that there is 
I 
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a decrease in doxorubicin concentration during storage of 
the frozen plasma samples (52). Eksborg et al. (1979) 
attributed this decrease in concentration tc be the result 
of a change in the plasma matrix. This conclusion came 
from the observation that the amounts of precipitate in the 
thawed plasma samples increased with increasing storage 
time. It is likely that doxorubicin is adsorted on the 
precipitate, which in turn decreased the degree of 
extraction into an organic phase (52). If this is the 
cause of decreased concentration in frozen sample, it is 
hoped that the Sep-fak method (the new method developed in 
this study) could overcome this flaw. 
Since no direct contact between the plasma and organic 
solvent is present in this Sep-pak methcd, the tOSsibility 
of C-18 tonded-phase silica stripping doxorubicin from its 
adsorbent is high. Additionally, the effects of the numter 
of freezing/thawing cycles and of the storage time on 
doxorubicin concentration of frozen plasma samples is under 
investigation. The comparison of these twc factors by 
freezing and thawing frczen plasma samples at different 
time intervals could determine the optimal storage 
condition. If the storage time plays a majcr role, it 
would be advisable to shorten the storage intervals tet•een 
freezing/thawing. Otherwise, the repeated phase~ of 
freezing and thawing shcuiu be avoid as often as possitle. 
( 
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2. The pH-dependent Ionization of Doxoruticin 
The evidence of enbanced statility of many drugs when 
the hydrogen-ion concentrations are maintained within a 
narrow range of pH, as well as of progressively decreasing 
stability when the pH departs from the CFtimuu range, is 
abundant (24,41,51,55). Stability of a chemical may result 
from gain or loss of a proton by a substrate molecule, 
which reduces the reactivity of the molecule. In aqueous 
solution, instability may arise through the catalytic 
effect of acids or bases; the former by transferring a 
proton to the substrate, the latter by accepting a proton 
(55) • 
~hat doxorubicin is stable in acidic media and 
unstable in more alkaline ones is well kncwn. ihis 
~henomenon results from the different ionized fcrms exist 
in solutions of different concentrations of hydrogen ion. 
ihese ionized forms not only exhibit different 
characteristics in stability, they also have different 
electronic absorFtion spectra. An ionization diagram 
postulated by sturgeon and Schulman is presented in Fig. ~, 
which shows the relationship among these ioni2ed s~ecies 
(56) • 
( 
0 0 
0 OH 
Zwitterion 
0 
II 
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Figure 3. The protolytic equilibria of doxorubicin 
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From the listed dissociation acid constants in Fig. 3, 
it is cbserved that doxorubicin has several ionizatle 
functional groups which are cf similar acidity (56). 
Therefore, overlapping protolJsis and 
possible. lhere is an indicaticn that 
eguilitria 
three or 
absorbing Sfecies are fresent in the soluticns of pH 7-12 
region because no distinct equivalence-point region is 
shown in titration curves (56,57). The acid disscciation 
constant of 
8.22, which 
the monocation to form the neutral molecule 
implies that a significant amount 
is 
of 
doxorubicin is present as neutral form in solution slightly 
above this pH value. This coincides with the fact that 
maximum distribut{on of doxoruticin in organic phase occurs 
at alkaline media (pH 8.3) (41,5~. Due to the existing of 
more than one ionized species in pH 7-12, the degradation 
process which happens much faster in strongly alkaline 
media may be due to the instability 0£ one or more of tbe 
ionized species. It is hoped that from this study of the 
effects of pH on doxoruticin statility, more information 
regarding the relationship between ionization and statility 
may be found. It should te ncted that the pKa values 
listed in Fig. 3 are only apprcxi~ate since 
self-association of doxorubicin influences the data frcm 
cne report to ancther (57). 
In developing method of analysis for doxorubicin, 
( 
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careful choice of pH and the analytical wavelength is 
necessary. The prevalence of only one emitting species 
having intense fluo~escence in the pH 1-7 region suggests 
that the fluorescent analysis of doxorubicin should te 
carried out in acidic solution (56). The infcrmation of 
the ionization of doxorubicin also provides the rational 
basis for alkalinizing agueous phase during extraction 
process. 
( 
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D. Protein Binding Study 
1. Scope and Purpose of This Study 
Many drugs interact with plasma or tissue protein to 
form a drug-protein complex. Comflexation of a drug with 
protein, i.e., drug protein binding, can influence the 
therapeutic, pharmacokinetic and tc~icologic actions of the 
drug (58). Only free or untound drug can ~ass through 
cellular membranes and reach the drug rece~tors or become 
eliminated (58,59). This relationship is shown in Fig. 4. 
However, only bindihg of drugs to plasma proteins has teen 
extensively studied primarily because the flasma is readily 
accessible to sampling, can be easily separated into its 
constituent macromolecules, and is easily guantitated. 
Tissue binding has none of these advantages and, as a 
result, knowledge of the qualitative and guantitative 
aspects of the tinding of drugs to tissue components is 
fOorly understood (59). Wagner (60) and Gillette (61) have 
pointed out that tissue binding may be much more important 
pharmacokinetically than plasma tinding. Owi~g to the 
difficulties to perform such a study, therefore, study of 
the plasma binding is the main goal of this study. 
The major component of flasma protein responsitle for 
drug bind~ng is albumin, a protein molecule with a 
tissue storage 
T + X ~ TX 
-
plasma 
PX 
I primary drug action 
-_,x ---- ------ -- X + R r==:= RX 
metabolic 
disposal 
/ 
,. ' 
' 
' 
' 
') 
E + X + Y ~ EXY 
Jr 
z----------, 
I 
I 
I 
I 
I 
I 
I 
'4- .. 
excretion 
Note: The size of each compartment has no physiological meaning 
Figure 4. The postulated influences of plasma protein binding upon 
primary drug action 
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molecular weight of 69,000. Albumin is synthesized ty 
liver and has a half-life of atout 17 to 18 days in flasma 
(147,148). In the body, despite the large molecular 
weight, albumin is not exclusivelu retained in the plasma, 
but also distributed extravascularly into skin, muscle, 
liver, spleen, etc. (5 9) • Normally, the albumin 
concentration is maintained at a relatively constant level 
within the plasma comfartment at about 3.5-4.5 ~ (w/v) or 
-4 5.0-6.5 x 10 , M (58,59). The maintenance of a somewhat 
constant intravascular mass of protein (in fai:ticular, 
albumin) is physiologically critical tecause circulating 
intravascular protein is the principal determination of 
plasma vclume (58,59). The change in plasma volume and in 
the free drug levels induced ty a change in altumin 
concentration may produce significant differences in 
pharmacologic e£fects froviding the fraction tound of this 
compound is high (58). 
rirugs bind to albumin ty either a reversitle or 
irreversitle process. In the case cf irrevei:sitle drug 
binding which cccurs rarely, the drug is chemically 
activated and attached permanently to the protein, usually 
by covalent bonding. thus, the permanently prctein-tound 
drug is unavailatle for therapeutic use (58) • ~ben drug 
protein binding is reversible, the binding is initiated by 
electrostatic forces and the resulting complex is further 
( 
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stabilized by van der Waals forces, sometimes a 
configuration change may occur to stabilize the ccnplex 
(61). Therefore, the protein-bound drug act as a depot, 
slowly releasing the active drug and replacing the free 
drug which is eliminated, i.e., there is an eguilitrium 
state between free and bound drug (58.61). 1hus. protein 
binding cf a drug can influence the distritution and 
elimination of the compoULd itself as well as the duration 
and intensity of the pharmacologic effects (59). However, 
evidence exists that only in case of highly lcund agents 
will binding be important in a practical sense (58.59,62). 
Quantitative information iegarding the fracticn bound 
of doxorubicin that binds to albumin was, however, 
unavailable. Harris and Gross (1975) tound that an extent 
of 50 ~ of doxorubicin was tound to rabbit and human plasma 
using the ultracentrifuge method (63). Chen et al. (1978) 
re-analyzed the data of Harris and Gross. and determined 
the fraction bound in the therapeutic plasma concentration 
range was 0.9 rather than 0.5 with no further explanaticn 
for such a change {64). These reforts leads to a fact that 
an accurate and detailed quantitative information regarding 
protein binding cf dcxorubicin is needed. Since the l~ 
vitr~ experiment should be performed in a slightly alkaline 
medium and the long period of time, 13 hours, is required 
to perform such a studj using ultracentrifuge method (63). 
It appears that the stability factor of doxorubicin should 
be considered. 1his study of doxorubicin tindirg kinetics 
iil vitro can yield information that is valuatle in the 
pharmacokinetic study of doxorubicin. 
2. Theory of Protein Einding 
The kinetics of reversible drug-protein binding can be 
described by the following equation (58,62). 
r ( 2 . 1 ) 
r : molar ratio 
K : association constant 
Cf: the concentration of free doxorubicin 
This eguation describes the simplest situation, in 
which one mole cf drug binds to one mole of protein in a 
1:1 complex. The extent of the drung-protein complex 
formed is dependent upon the association binding constant, 
K. 
However, protein molecules are quite large compared to 
drug molecules and may contain more than c~E type of 
binding site for the drug. If there is more than one type 
( 
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of binding site and the drug tinds independently on each 
tinding site with its own association constant, then 
Eg. 2.1 exfands to the following (58,62): 
o r 
r = 
n 
r =L. 
i= l 
+ 
+ .. ••• 
( 2 . 2 ) 
where the numberical subscript represent different types of 
binding sites, the K's represent the association constants 
and the n's represent the number of binding sites per 
molecule of · albumin. 
1he values of the association constants and the numter 
of binding sites can te obtained by various gra~hic methods 
Scatchard plot is one of these graphic technigues which 
spreads data to give a tetter line for the estimaticn of 
the binding constants and binding sites. And due to this 
ability of spreading data points, Scatchard plot is the 
most common technique employed in frotein binding studies. 
For a single binding site situation, the fellowing is 
obtained (58,62) 
N· K - r- K ( 2 . 3) 
( 
30 
A graph constructed by plotting r/(Cf) versus r yields 
a straight line with the intercept being N*K and the slope 
being -K. However, some drug-protein binding data produce 
scatchard graphs of curvilinear lines, i.e., more than cne 
type of binding sites exist (58). And non-linear fitting 
mathematical model using computer techniques is more 
suitable for such a complicated analysis rather than the 
direct estimation from the Scatchard plot. Using computer 
techniques, one can obtain best estimation for each Ni and 
each Ki (65). Also, the precision of the fitting procedure 
in the neighborhood of a least-sguares scluticn can te 
examined (65). The development of such a computer program, 
however, is closely related to the binding method used to 
obtain raw data. 
3. Binding Method and the Computer Nonlinear Fitting 
program 
The degree of binding of drug molecules by ~rotein can 
be estimated by using several methods such as dialysis, gel 
filtration, ultracentrifugation, and ultrafiltration. 
1hese methods yield similar, but net always identical 
results (62,66). Among them, a continuous ultrafiltration 
cbserves the binding behavior under various ccncentrations 
of drug with one single run. Thus, it provides a more 
accurate observation the the discrete data cbtained ty 
( 
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other methods (67, 68) • 
Ultrafiltration is a process which se~arates dissolved 
molecules en the basis of molecular size. A moderate 
pressure (5 to 50 p.s.i) forces the solution and low 
molecular weight solutes through the thin membrane, but the 
~assage of higher molecular weight solutes is hindered 
(66,67). Semipermeable dialysis membranes, e.g., Diaflc 
membranes, have been used as filters (67). In addition to 
the much higher efficiency of Diaflo membranes relative to 
those used in equilibrium dialysis, these memtranes are 
also available with a spectrum of molecular size for 
reten tivities. 
Blatt ~! ,g.l.:. 
ultrafiltration method, 
have demonstrated 
coupled with the 
that the 
maintenance of 
fixed volume in the sample compartment during the run, 
perf crmed protein binding studies in a manner similar to 
the ccnventional equilibrium dialysis, tut without the 
protracted dialysis times common to the latter method (67). 
In a continuous process, it is fossible to determine 
single 
of 
experiment (in a few 
ultrafiltrate, carefully 
changes in binding from a 
hours) by taking aliguots 
measuring the volume, and calculating the drug 
concentration (67,68). In comparison to dialysis method, 
continuous ultraltration has the advantages of cttaining a 
( 
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series of data in a single run, separating tte free drug 
ever a short period of time, and the conservation of 
materials, particularly the expensive altumin. In 
addition, the memlrane tinding of the drug can be easily 
corrected by a tlank run, i.e., without altumin present in 
the filtration cell (67,68). 
A series of data regarding molar ratic 
doxorubicin concentration (Cf) can be 
(r) and 
obtained 
free 
ly a 
continuous ultrafiltration method. And accorditg to Eq. 
2.2, a nonlinear computer program can be used to find the 
best estimates for n, each Ni and each Ki (65). 1his 
program also makes correction for the void volume of the 
system and the non-ideal behavior cf the memtrane. In 
comparison with the direct estimation from a Scatchard 
plot, a precision for the fitting procedure is provided ~ and 
the probable error for each· Ki is calculated. 
With this mathematic binding model estatlished for 
doxorubicin, the effects of the physiologic ccnditicn cf a 
patient on protein binding can be ~redicted. if 
doxorubicin which has a small therapeutic index falls in 
the category of •strongly bound', it would become necessary 
to consider protein tinding as a vital parameter in the 
characterization of its tehavior. 
( 
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Ae .Materials 
1. Chemicals 
Doxorubicin hydrochloride, Sigma Chemical 
(D-1515, Lot 21F-0241) 
Daunoruticin hydrochloride, Sigma Chemical 
(D-4885, Lot 88C-0207) 
Dimethyldichlorosilane, Pierce Chemical Co., 
Lot 092581-82) 
33 
Co., 
Co., 
(83401, 
Hexane, Fisher Scientific Co., (H-302, Lat 793076) 
.Methyl alcohol, Burdick & Jackson Latoratcries inc. 
(Lot AH749) 
Phosfharic acid, 853, Fisher Scientific Co., 
Lot 715056) 
Silver nitrate, Mallinckrodt, (2160, Lot HN) 
(A-260, 
Acetoni trile, Waters Associates, Inc., ( 84935, lot 
081314) 
Sodium lauryl sulfate, Ruger Chemical Co., lnc., (lot 
C713284) 
.Monobasic ammonium phosphate, General Chemical 
Division, (1312, Lot K202) 
( 
( 
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Acetic acid, glacial, Fisher Scientific Co., 
lot 712081) 
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(A-38, 
Chloroform, Waters Associates, .Inc., '84939, AF612) 
Magnesium chloride, Fisher Scientific Co., (M-33, lot 
706396) 
Methylene chloride, Fisher Scientific Co., (D-143, Lot 
711908) 
~oluene, Fisher Scientific co., (T-324, Lot 742939) 
Uracil, Eastman Kodak Co., (2504, lot A 12A) 
Hydrochloric acid, Mallinckrcdt, (2612, Lot KMBV) 
Sodium hydroxide, Fisher Scientific Co., 
720859) 
(.S-318, lot 
Albumin (human), fraction V power, Calbiocbem-Behring 
Corp., (12666, lot 903€35) 
Citric acid, Amend Drug and Chemical 
26698M31) 
Co., (Lot 
Eoric acid, Amend Drug and Chemical Cc., (let C611549) 
MonoFctassium phosphate, 
(D-286, let 722964) 
Fisher Scientific 
Disodium phosphate, Merck, '74241, Let 62875) 
2. Equipment and SUFFlies 
Vortex-genie, Scientific Industries, Inc. 
Sep-pak cartridges, Waters Associates, Inc. 
Plastifak syringes, Fisher Scientific Co. 
Co., 
( 
Sample vials and sample rack of Fisher Model 190 
Sample concentrator, Fisher Scientific Cc. 
Tissue grinders, Potter-Elvehjem type, and telphon 
pestles, Thomas Scientific Co. 
Magni Whirl constant temperature bath, Elue M Electric 
Co. 
Vacuum pump, Model 0211-V36A, Mil~ipore 
HA memtrane filters (0.45 Mm), ltillipore 
FA memlrane filters (0.5 Mm), Millepore 
~Eondapak C-18 column, 3.9 mm (ID) x 30 cm, 
Waters Associates, Inc. 
( 10 .um) , 
Radial-pak B liguid chromatographic cartridge 0.8 mm 
(IDJ x 10 cm, (10 Mm), Water Associates, Inc. 
Pellicular media for HPLC, Octadicyl (C-18) gLoup, 
(30-38 Mm), Whatman, Inc. 
Model RCM-100 Module (of the radial compression 
separation system), Waters Associates, Inc. 
Model 6000A solvent delivery system, waters 
Associates, Inc. 
Model 420 fluorescence detector, Waters Associates, 
Inc. 
Guard Column, 3.2 mm (ID) x 5 cm, Rainin Instrument, 
cc. Inc., 
WISP (~ater Intelligent Sample Processor) 710B, Waters 
Associates Inc. 
Data Module, Waters Associates, Inc. 
( 
Expandomatic SS-2 pH meter, Beckman 
Dynac II Centrifuge, Clay Adams. 
Mettler Balance, type H6T, Mettler Instrument Corp. 
Mettler Balance, type H16, Mettler Instrume~t Ccrp. 
Torsion Balance, The Torsion Balance Co. 
3€ 
Series-parallel R-C combination box Model 1140, 
Electric Instrument Co. Inc. 
SC 102 Active filter, Analabs 
Ultrafiltration unit, model MS, Amicon 
Diaflo ultrafilters, PM10, Amicon 
Centrifree, Amicon 
( 
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E. Assay Method 
Doxorubicin, its metabolites and daunorulicin (the 
internal standard) 
by a new procedure 
were extracted from biological samples 
developed tc replace tbe tedious 
organic extraction method. In this new conventional 
method, Sep-pak cartridges are used to prepare protein free 
samples for HPLC analysis. 
self-contained and packed 
~hese 
with 
cartridges are small, 
liguid chromatographic 
separating materials optimized for sample preparation and 
cleanup procedure. Compounds of interest (doxoruticin, its 
metabolites and daunoruticin) can te retained in this 
chromatographic ted while materials such as prcteins and 
nucleotides pass through. Compounds of interest can then 
be eluted with an appropriate solvent. 
Biological samples of interest are human and rat 
plasma, and rat tissues (e.g., liver, kidney, lung, heart, 
and train) which were kindly provided by Roger williams 
General Hospital. Flasma, · being a cell-free fluid, could 
te directly applied to Sep-pak cartridges whereas tissue 
processing required homogenization. 
homogenization, troke into a 
Cells in tissue, upon 
mixture of cellular 
components, such as neucleotides, proteins, rilosomes, 
mitochondria, etc.. ~hen doxorubicin was exposed to such 
attractive substrates, especially nuclectides and 
( 
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ribosomes, it was highly possitle that dcxoruticin (DCX) 
Existed mostly as the DOX-DNA complex in the homogenate 
(39). ~his was further confirmed by the i~ vit£~ tinding 
studies of doxcrubicin and DNA, which showed a high 
association constant of 0.37 - 11.61x10 6 M (47). 
The unsuccessful extraction cf doxorubicin from tissue 
homogenates indicated that a stronger reaction ~as needed 
to dissociate the DCX-DNA complex rather than the simple 
partition phenomenon used in the organic extraction method 
(42,46). ~he use of silver nitrate proposed ty Schwartz 
solved this problem ty pfecipitating nucleotides and 
proteins and thus free doxorubicin from its tinding sites 
(39). But in the case of piasma samples, the only possitle 
substrate is albumin. The organic extracticn method has 
been demonstrated to te sufficient to disrupt the tinding 
forces between doxorubicin and albumin (31,36-40). 
Therefore, there are different approaches for handling 
samples, which are dependent on the origins of these 
samples, and will be further explained in the following 
procedures. 
Human and rat plasma, and rat kidney samples were 
available for pharmacokinetic studies. Plasma samples from 
four cancer patients with various disease were assayed. 
Doxorubicin was administered as a single bolus dose in all 
39 
these patients and plasma samples were taken at different 
( 
time intervals. tata were analyzed ty AUTCAN tc calculate 
the pharmacokinetic parameters. It would ~e of interest to 
see whether these ~arameters, such as half-life, peak 
concentration, vclume of distribution, would be influenced 
by the disease state, age and sex of each patient. 
Plasma and kidney samples of both young and old rats 
were assayed by the Sep-pak method. This study was 
inspired by the deeply concerned effects of age on 
pharmacokinetics. Pharmacokinetic studies in geriatrics is 
of substantial interest with the recognition that the aged 
constitute an increasing proportion of patient POEUlation 
(69-71). It is hoped that from this small scale study, 
some contribution may be made in this field. However, the 
results may~ be partial and incomplete since only the plasma 
and kidney samples were analyzed. 
Plasma arid kidney samples of both groups (the young 
and the old) were taken at 0.5, 1.5, 4, 10, 24, 50 hours 
after the tail-vein injection of 15 ng/Gm cf dcxorubicin. 
lhere was one rat at each time interval per sample group 
(A,B,C,D) and 24 rats were used in this study. ~he age of 
the young rats (group A and B) were 2 months and those of 
the old rAts (group C and D) were an aveTage of 2 years. 
Samples were all frozen at -20°C until analysis. Data from 
( 
( 
40 
this study was also calculated by AUTCAN and compared 
tetween these groups. 
1. Silanization of Glass Equipment 
All glass egui~ment, with 
injection syringe, was silanized 
with dichlorodimethylsilane (5 %, 
the exception of the 
before use ly treatment 
.by volume) in .hexane 
overnight, followed by washing with methanol. 
In order to exhibit the effect of silanization, 
extraction was also carried out with the ncn-silanized 
glassware. Two sets of glassware (the · silanized and the 
non-silanized) were used during extraction procedure, after 
the preparation cf stock solutions cf doxorubicin and 
daunorubicin. 
2. Plasma Samples 
0.1 ml of internal standard (daunorubicin) solution in 
an appropriate concentration was added to 1.0 ml plasma 
sample. Since doxorubicin concentration fell from 1,0uO 
ng/ml to less than 100 ng/ml during a study, it was 
necessary to use two concentrations of daunoruticin 
solution, either 2 or 8 ilg/ml, tc make the most accurate 
and sensitive detection. After the additicn cf internal 
41 
standard, the sample was processed ly the ~ep-fak methcd. 
3. Tissue Samles 
Frozen tissues were thawed and samples ranging from 
100 to 400 mg (dry weight) were taken. 0.1 ml of 8 ~g/ml 
daunorubicin solution was added to the tissue and sample 
was homogenized in 2 ml of water emflcying a 
Potter-Elvenjem homogenizer. 0~3 ml of 50 % silveL nitrate 
(freshly prepared, weekly) was then added to the homogenate 
and mixed well with the pestle. Finally, 2 ml of water 
were added to each sample. 
Schwartz employed 0.1% sodium lauryl sulfate solution 
to facilitate the lysis of L 1210 ascites cell in the 
prescence of silver nitrate (39). lne effectiveness of 
sodium lauryl sulfate solution in tissue homogenates was 
also tested. !his test was performed by adding ~ ml of 
0.1% sodium lauryl sulfate to the silver-icn-treated 
homogenates. Additionally, the efficiency of 
Fhosphate buffer to extract doxoruticin and 
was investigated. This was 
pH 7.4 
related 
dcne .t y compounds (72) 
homogenizing the 
l:uf fer (pH 7. 4) 
sample in two portions cf 4 ml phosfnate 
after the addition of the internal 
standard. Homcg~nates, obtained from respective 
procedures, were then centrifuged at 2,000 r.p.m. for 10 
( 
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minutes. The clear supernant was reserved for extraction. 
4. Extraction Methods 
a. The Sep-pak method 
To avoid adsorption of doxorubicin onto glass, plastic 
syringes were used in this procedure. The 
cartridge was first wetted by c ml of methanol, follow€d by 
10 ml cf water in order to remove residual methanol which 
may precipitate proteins and elute compounds of interest 
prematurely. The plunger was then removed from the syringe 
and sample was introduced with Sep-pak cartridge attached 
to the tip of syringe. For plasma samples, the 
introduction was simply a direct application. For tissue 
samples, it was the clear supernant of the ceDtrif uged 
homogenates. After removing the non-retainable porticns of 
sample, the Sep-pak cartridge was washed with 12 ml of 
water to remove any residual protein or silver ions. The 
retained compounds in the cartridge were then slowly eluted 
- 3 
with 7 ml of acid-methanol (5 X 10 M pbcsphoric acid in 
methanol) into an evaporation sample vial. 
The strong acidity of this acid-methancl &ixture (pH 
2.34) may promote the possible hydrolysis of the glycosidic 
bond of dcxorubicin. Therefore, two drops of 20~ NaCH in 
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methanol were immediately added to the individual eluent to 
adjust the pH to around 6. The pH adjusted eluents were 
then concentrated in a 40°C water bath until sam~le volume 
was approximate 1 ml (about 3 hours). Samples were then 
analyzed by an HPLC system consisted of a solvent pump, a 
C-18 chromatographic column, a f luorometeL and a data 
acquisition system (Data Module, Waters). 
b. The organic solvent extraction methcd 
An existing organic extraction method was tested in 
order to determine whether extraction efficiency of the 
Sep-pak metbod was superior or not. 0.1 ml of 2 Mg/ml 
daunorubicin solution was added to 1.0 ml of spiked plasma. 
Two drops of 0.1 N NaOH solution were then added to the 
sample to adjust the pH for maximum extraction. 4 ml of a 
chloroform and methanol mixture (4:1) was used to extract 
doxorubicin thrice. 
sample vial and 
Extract was placed in an evaforation 
concentrated in the same manneL as 
previously described. Samfles were then tlown to dryness 
using nitrogen gas and redissolved in 1 ml of methano~ for 
HPLC analysis. 
( 
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c. Calculation of recovery rates 
Three methods were used to · measure the atsolute 
amounts of doxorubicin recovered from extracts. The first 
method was the standard addition method which used the 
internal standard to compensate the guantitation 
differences caused by complex sample matrices. In this 
methcd, the processed samp~e from spiked flasma was 
chromatographed first. 1he sample was then s~iked with a 
known amount of doxorubicin and guantitated again. The 
change in the peak height {PH) of the unspiked daunorubicin 
{IS) peak was used as an adjustment factor to correct for 
the concomitant sample dilution The fcrmula fer the 
standard addition methoa are: 
adjusted PH 
of DOX 
PH of IS before spike 
PH of IS after spike 
* PH of DOX spiked 
amount in 
the sample 
amount spiked * PH of DOX unspiked 
adjnsted PH of DOX - PH of DOX unspiked 
Tbe recovery rate could then 
following: 
be 
amount in the sample 
calculated as 
recovery rate ·* 100% 
amount spiked before extraction 
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The second one was the direct method whose major 
difference was the addition of the internal standard after 
concentration of the extracts. The final addition of 
. 
daunoruhicin was to correct the sample volume differEnces. 
The peak heights (PH) of doxorubicin and daunorubicin were 
measured against the standard doxoruticin and daunorubicin 
solution of the same concentration. Recovery rates could 
be calculated as the following eguaticns: 
~djusted PH 
of DOX 
recovery rate 
PH of DOX * PH of IS in STD 
PH of IS 
adjusted PH of DOX 
* 100% 
PH of DOX in STD 
where DOX stands for doxorubicin and STE represents 
standard solution. 
lhe third one was the elution method which compared 
doxorubicin concentration of tbe unconcentrated eluent from 
a Sep-pak cartridge with that of a standard solution. lhis 
was done bj assaying the drug concentration in the eluEnt 
from a spiked plasma or tissue sample before concentration 
in a water bath. The standard scluticn was Frepared by 
adding the same s~iked amount into the same volume (as that 
of the eluent) of acid-methanol mixture. And thE recovery 
rate was calculated ty the following eguaticn. 
( 
rec every 
rate 
cone of DOX in the eluent 
cone of DOX in STD 
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* 100 % 
While the extraction efficiency of the Sep-pak method 
was calculated by all three methods, that of the organic 
solvent extraction was only calculated ty the 
method. 
5. High Performance Liguid Chrcmatcgraphic System 
a. Chromatographic system for analysis 
Various liquid chromatographic systems 
developed for the analysis of doxorubicin 
have 
and 
direct 
been 
its 
metabolites (15,24,34,35). However, in the present study, 
reversed-phase chromatography was used f cr all assays owing 
to the advantages descrited before. 
A 3.9 mm (IL) x 10 cm stainless steel colunn, ~acked 
with 10 Mm particle-size octadecyl-silica (MBcndapak C-18, 
Waters) was used. An isocratic mobile phase consisted of 
600 ml of methanol and 400 ml of 0.01 M NH+E 2 204 solution 
(to the latter, 5 ml of acetic acid was added). This 
~obile phase (final pH=4) will be referred tc as mobile 
phase 1, the methanol and monoammonium phosphate solution 
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(60:40) mixture. The flow rate was 1.0 ml/min aLd resulted 
in a pressure cf 1,500 p.s.i.. lhe motile phase was 
degassed by filtering through FH type filter (0.5 ~m, 
Millipore) under vacuum. All separations were performed at 
ambient temperature. Samples were injected usinq an 
automatic sample processor (WISP, Waters). 
The detection unit consisted of a filter-type 
flucrescence detector (Model 420, Waters) and a SC 102 
active filter (Analab). The fluorescence detectcr measured 
fluorescent luminescence with an emission filter of a tand 
of wavelengths around 254 nm and an excitaticn filter that 
cut off wavelengths greater than 495 nm. 1be fluorescence 
detector was eguipped with a 10-Ml flow cell. The SC 102 
active filter maintained peak amplitudes while reducing the 
baseline noise with no signal distortion. Chromatograms 
were recorded and peak height areas (referred to as peak 
heights in the following text in order to distinguished 
from total peak area) were integrated by a data acguisiticn 
system (Data Module, Waters). 
All sample injection was performed by the automatic 
sample processcr (WISF, Waters). tue to the wide 
physiological range of doxorubicin concentrations 
(15,25,31,44,73-75), the adjustment of the injection volume 
of sample was necessary (Appendix). lhere aas also a 
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lowest detection limit which required the signal tc noise 
ratio to be larger than 5. This restriction in detection 
limit required that the concentrations of daunoruticin 
changed correspondingly to those of doxorubicin (AFFEDdix). 
The automatic sample processor resfcnded accurately to both 
adjustments. 
t. Measurement of the efficiency of separation 
The sefaration efficiencies of a chrc~atograFhic 
system can be easily described by parameters such as 
capacity factor (k'), selectivity (~), thecretical flates 
(N) and resolution (R). in order to measure and calculate 
these parameters, the void volume of the system should be 
determined first. 1he void volume of C-18 column 
~Bondapak, Waters) was measured by injection of 
non-retainable uracil with motile phase being a mixture of 
acetcnitrile and water (60:40). 1he retention times cf 
doxorubicin, dauncrubicin, doxorubicinone (the aglycone) 
and doxorubicinol (the major metabolite) were determined ty 
using the same cclumn tut with mobile phase 1, the methanol 
and monoammcnium Fhosphate solution (60:40) mixture. 1hen 
the capacity factors (k'), number of effective flates (N), 
selectivities (~), and resolutions (R) of er among these 
four comfounds were calculated. 
( 
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Daunorubicin and doxorubicin were ~urchased from Sigma 
and used as received. Coxorubicinone can be synthesized by 
hydrolysis of doxorubicin in 1 N HCl at 100°C for 30 
minutes (89). Eut · doxorubicinol ~as attained fro~ the 
tissue samples. Due to the lack of doxorubicincl standard, 
it would be necessary tc verify its existence ty comparing 
literature. data with more than one chromatographic systems. 
In addition, it would be of interest tc aeasure the 
efficiencies of these systems and to make sure that the 
choice of the analysis system (Sec. Sa) did not sufier in 
efficiency and . sensitivity. The second chromatographic 
system consisted of the same C-18 column (MBcnda~ak, 
Waters) and a motile phase prepared from 0.01 M ~hcs~horic 
acid in acetonitrile solution. Various fractions of 
acetonitrile were tried to obtain 
profile and the highest sensitivity. 
ml/min and produced a pressure of 
the best separation 
The flew rate was 1.0 
1,000 f.s.i. lhe void 
volume was the same as with system 1 since the same column 
and tuting wer€ used. 
!he third system consisted of a normal phase, 
Badial-pak E chromatographic cartridge (10 Mm, Waters), and 
mobile phase being a mixture of chloroforn, methanol, 
glacial acetic acid and J.O mM magnesium chloxiJe solution 
(720:210:40:30). 1his Radial-pak cartridge was properly 
pressured in the Model RCM-100 Module. The flew rate was 
( 
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2.0 ml/min with pressure being 1,000 p.s.i.. 1he retention 
times cf all four compounds {doxorubicin, doxoruticinone, 
doxorubicinol and daunorubicin) were measured with the same 
detection unit and recorder. !he void vclume of this 
system was obtained by injection of the ncn-retainable 
toluene with mobile phase being methylene chloride. ether 
parameters like K', ~, N, R, were also calculated. As for 
measuring the sensitivity of eacb system, samples of the 
same concentrations of doxorubicin (500 ng/ml) and 
daunorubicin (1 ~g/ml) in respective motile phase were 
injected and the peaks measured. 
All mobile phases were degassed by the same vacuum 
pump method and separations were performed at ambient 
temperature. 
( 
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c. Method for Statility Studies 
1. Stability of Doxorubicin in Solutions 
The stability of doxoruticin was measured in citrate -
phosphate - borate buffers with pH ranging from 2.00 to 
11.90. Because all spiked samples were prepared from 
aqueous solutions of doxorubicin, its staLility in water 
was also measured. Additionally, the statility test was 
also performed in acid-methanol (eluent in Sep-pak method), 
mobile phase 1 (the 0.01 ~ mcnoammonium phosphate 
solution-methanol (60:40) mixture), and pH 7.0, 7.4 
fhosphate buffers. Tbe phosphate buffers was included in 
this test because it was used in the protein tinding 
studies (pH 7.4) and to detect the effects of cbanging the 
buffering agents. 
Solutions of 1 Mg/ml of doxorubicin in citrate 
fhosphate - torate tuffers, water, acid-methanol, mcbile 
phase 1 and phosphate buffers (~H 7.0 and 7.4) were 
analyzed by HPLC at a~propriate time intervals (dependent 
on the rate of degradation). 1he notile phase for this 
study was 0.01 M ~hosphoric acid in 40 ~ acetcnitrile 
solution. All samples were prepared in triplicate anu 
analyzed twice. 
2. Stability of Doxoruticin in flasma 
The effects of storage time and the IJ umber 
c: ,.., 
... ~ 
of 
freezing;thrawing cycles on the stability of doxoruticin in 
plasma were investigated. Frozen spiked plasma samples of 
500 ng/ml doxoruticin were thawed at room tem~erature at 
intervals of 1, 3 and 5 days. Samples that were thawed 
after staying frozen for 10, 30 and 50 days served as the 
control groups. 0.1 ml of dauncrubicin solution (7. 5 
~g/ml) was added to 1.0 ml of a thawed sample and Se~-pak 
extraction method was used to extract both compounds frcm 
plasma. 1he concentrated eluents were analy2ed ty a 
reversed-phase HPLC system while mctile phase ~as prepared 
from 0.01 M phosphoric acid in 40 ~ acetonitrile soluticn. 
All samples were ~prepared in triplicate and analyzed 
thrice. 
Eksborg ~1 al~ proposed that the degradation may te 
caused by the adsor~tion of doiorubicin onto the 
precipitate of thawed sample (see I~trcduction c.1, 52). 
Theref cre, a visual check-up for the appearance of thawed 
sample was also performed. 
( 
53 
D. Methods for Protein Binding Studies 
1. The Ultrafiltration Methods 
Ultrafiltration was performed with an Amiccn Model M8 
ultrafiltration unit. A PM 10 Diaflo ultrafilter was used 
to retain particles of moleculaL weights larger than 
10,000. Eefore performing a continuous ultrafiltration, a 
direct 
first 
(i.e., a •wash-out') 
to determine the 
experiment was 
appropriate 
concentrations used in a continuous method. 
carried out 
doxarulicin 
~he •wash-out• procedure entailed the filtration cell 
with 8 ml of doxorubicin solution of known ccncentraticn in 
4 % albumin sclution (in pH 7.4 phosphate tuffer). 
Ultrafiltration was commenced with a stir bar connected to 
the cap of the filtration cell. Agitaticn wa~ needed to 
maintain uniform bulk ccmposition in this compartment and 
to prevent polarization or caking out of high molecular 
weight species against the membrane surface (67,68). A 
pressure of 10 
free (unbound) 
p.s.i. of nitrogen gas was used to ~ush the 
doxorubicin through the Diaflc memtrane. 
Various concentrations cf doxorubicin were tried until a 
significant amount cf doxorubicin in ultrafiltrate was 
detected. lhis method also provided a rough estimaticn cf 
the fraction of doxoruticin bound by albumin. A tlank 
( 
( 
•wash-out• experiment was 
guantitate the fracticn 
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simulta~eously carried out tc 
of doxoruticin that tound to the 
Diaflo memtrane itself. 1herefore, two sets cf direct 
ultrafiltration experiments were performed; one with 
doxorubicin and 4 3 albumin solution in the filtration 
cell, and the ether (the blank run) with only doxoruticin 
solution. However, it should te pointed out that no more 
than 10 j of t~e fluid volume in the filtratic~ cell (i.e. 
O. 8 ml) was allowed to collect otherwise the resul.tant 
change of the albumin concentration may significantly 
affect binding. 
From these •wash-cut• experiments, the concentrations 
of doxorubicin used in the continuous ('wash-in') method 
could be determined. In this •wash-in' experiment, 50 ml 
of doxorubicin (5, 10, 15 Mg/ml respectively) in pH 7.4 
phosphate tuffer was placed in the reservior cell and the 
filtration cell was filled with 8 ml of 4 3 huuan altumin 
in pH 7.4 ~hosphate tufter. A pressure cf 10 ~.s.i. •as 
exerted on the reservoir cell to push doxoruticin into the 
filtration cell. At the same time, the same vclume of 
liquid was pushed out as the ultrafiltratee 1o prevent 
degradation of doxorubicin caused ty the high pH (pH 7.4), 
six drops of 15 3 HCl solution was immediately added per 
gram of the weighed ultraiiltrate to lower the pE tc arcund 
5. The pH adjusted ultrafiltrates were again weighed to 
( 
l 
compensate for this dilution effect. 
ultrafiltrates were analyzed using the 
previously described but with a mobile 
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lhe precessed 
EPLC system as 
phase of 0.01 M 
phosphoric acid in 35 ' acetonitrile scluticn. 
I.he Diaflo memtranes were highly stained ty 
doxorubicin, indicating sutstaintial memtrane binding. 
Correction for membrane tinding was accomplished by a llank 
•wash-in' experiment with the same concentration oi 
doxorubicin in the reservoir cell and no allumin (only 
phosphate tuffer) in the filtration cell. 1he 
ultrafiltrate thus collected was also treated in the same 
manner as previously described. lhe same tlank exp€riment 
was also performed in the •wash-out• method tc ccrrect totb 
membrane tinding and void voluae. 
2. The ultracentrifugation method 
An ultracentrifugation method was performed to see if 
the binding data did vary from one method to another as 
ethers have indicated (154,156). This was done ty using 
the disposatle Centrifrees (Amicon) and cnly one 
concentration of doxoruticin was covered due to the limited 
availability. 5 
solution (in pH 
Mg/ml of doxorubicin 
7.4 phosphate buffer) 
in 4 I allumin 
was added to th€ 
sample reservoir of a Centrifree. The Centrifree was then 
( 
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spun at 2,000 r.p.m. for 20 minutes. 1he filtrate thus 
obtained was weighed, neutralized with 15 ~ ECl soluticn 
and weighed again. lhe pH adjusted filtrate was assayed 
chromatographically and correction ior the dilution effect 
of neutralization was made. A tlank run, with no albumin 
in the samfle reservoir, was carried out to determine the 
nons~ecific adsorpticn cf doxorubicin to the memlrane. 
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( III. RESULTS ANI: I:ISCUSSICN 
A. The Assay Method 
1. High Performance liguid Chromatographic Systems 
The efriciencies and sensitivities of tnree HPIC 
systems were investigated and the results were shown in 
Table 1. Chromatographic parameters such as ca~acity 
factor (k 1 ), selectivity (~), number cf effective plates 
(N), and resolution (R) were calculated . for each system. 
Comparison was made and the suitable application of each 
system was indicated. 
a. The phosphoric acid-acetonitrile system 
This mode of HPLC system consisted of a MBondapak C-18 
column (Waters) and a mobile phase 0£ 0.01 M phosphoric 
acid in various fractions of acetonitrile solution. 1he 
highest sensitivity could le attained when the fracticn of 
acetonitrile was over 35 % (1able 1) • Although separations 
among compounds of interest (doxorubicin, its metatolites 
and daunoruticin) were improved by lowerin~ the fracticn of 
acetcnitrile, . the sensitivities were simultaneously lesser. 
Due to this phenomenon, it was suggested that suitatle 
alteration of the acetonitrile fraction te made to meet the 
( 
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HPLC system relative .relative specified 
al:sorbance absorbance uses 
of DOX of DAO ' 
(%) ( %) 
40%CH 3 CN 100.00 100.00 for stability 
studies 
353CH3 CN 100.00 100.00 for protein l::inding 
studies 
323CH~CN 63.73 69.38 no specific uses, 
the separation of 
doxoruticincl was 
not good 
30%CH3 CN 53.26 56.85 no specific uses, 
the separation of 
doxorubicincl was 
not good 
65%MeOH 36. 31 42.80 no specific uses, 
t.he separation cf 
doxorul:icinol was 
good enough 
603MeOH 30.74 31.98 good for assay 
of the l:iolcgical 
samples 
"\ 
213 CHCl3 34.23 69.29 the capacity f actores 
were tee small for 
all compounds 
*1 This refers to a reversed phase HPIC of a C-18 column and 
mobile phase being 0.01~ HiPO~ in acetonit.rile solution. 
lhe percentage of acetonitrile is assaigned. 
*2 This refered to a reversed-phase HPLC of a C-18 column and 
mobile phase being 0.01 M NH4 H~P04 solution and methanol 
mixture. The percentage of methanol is assigned. 
*3 !his refered to a normal-phase HPIC of Eadial-pak E column 
and mobile phase consisted of MeOH, CHC13 , MgCl~ solution, 
glacial CH3COOH (21:72:4:3}. 
*4 This measurement was performed with solutions of DOX 
(doxorubiciD 500 ng/ml) and DAU (daunorubicin 1~g/ml} in 
respective mobile phase. The variation was smaller than 
5 % and therefore is omitted from this table. 
Table 1. !be relative absorbances and separation conditions for 
HFIC systems 
( reguirements of each tyfe of doxoruLicin analysis. 
Mobile phase containing the highest fraction 
acetcnitrile, i.e., 40 %, was most suitatle for 
analysis of doxorubicin in stability studies (Fig. 5). 
to the low interferences in ~lasma and tuffers, · 
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of 
the 
DUE 
geed 
separation and 
whole process. 
high sensitivity were observed during the 
lhe retention times of doxoruticin and 
daunorubicin were 3.93 and 5.34 minutes respectively. 1he 
minimal requirement for a good sefaraticn in HELC is ta set 
up conditions so that the selectivities tali intc a range 
of 1.05 - 2.00, and rescluticns are greater than 1.5. 1be 
selectivity in this system between the nearest interference 
peak and doxorubicin in spiked flasma was 1,59 and that 
between doxorubicin and daunorubicin was 2.2e (Fig. 5.b}. 
The resolution was 1.64 between the former set cf compounds 
and 3.52 between the latter. 1he application of this 
mobile phase was also very economic in tiae and solvents. 
The analysis time of each sample was 5 ainutes for 
sta~ility tests in buffers and 7 minutes in plasma samples. 
The mobile phase containing 35 ~ acetonitriJe was used 
for all prctein binding studies. 
degree cf interference did 
As shown in Fig. 5, 
exist for the first 
some 
few 
fractions of ultrafiltrates collected. And this motile 
phase could effectively separate these interferences from 
( 
a. blank plasma sample in 40 % acetonitrile 
1 
_£ 
b. spiked plasma sample in 40 % acetonitrile 
! 
c. spiked buffer sample in 40 % acetonitrile 
d. ultrafiltrate sample in 35 % acetonitrile 
DO X (3. 93) 
DAU ( 5. 34) 
60 
DO X (3. 89) 
DO X ( 5. 70 ) 
DO X ( 5 . 65 ) 
e. sp i ked samp l e of t he neu tral ized phosphat e bu f fer in 35 % ac e ton itrile 
Fi gure 5. Th e chroma t og rams of doxorubicin and dau norubicin in t he phospho r ic acid -
accton itri l e system 
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doxorubicin without losing aDy degree of seDsitivity 
(1atle 1). 1he retention 
minutes. 1he selectivity 
time cf doxorubicin was 5.70 
between the last pea~ of 
interferences and doxorubicin was 1.39 and the rescluticn 
was 1.45 (fig. 5). 1he analysis timE of each fraction of 
ultrafiltrate was 1 minutes. 
Void volume fer the atove calculation of selectivities 
were measure by injection cf uracil with a motile phase of 
60 ~ acetonitrile solution. 1he vcid volu~e thus cttainEd 
was 2.83 ml. While these motile phases were efficient 
enough for stability and protein tinding studies, it was 
not until the fracticn of acetonitrile was as low as 30 % 
that the detection of doxorubicinol in tissues samples was 
possible. The chromatograms of the liver sampies in this 
mobile phase was shown in Fig. 6. 1he peaks of 
doxorubicinol a~d doxorubicinone were barely recognized. 
1he chromatographic parameters of the compounds cf interest 
were listed in Table ~- !he selectively and resolution 
tetween the last peak of interferenc~s and that of 
doxorubicinol were 1.12 and 0.52 respectively. The 
resolution was also poor tetween doxorubicincne and 
daunorubiciD. This motile phase was not applicatle for the 
assay of tissue and plasma levels. 
1he chromatcgra~hic data obtained by Ekstcrg showed 
--
a. blank liver sample 
:==~~============DDX (8.13) 
-==================>DAU (Jl1. 71) 
b. spiked I iver- sample 
l 
~~====~~~~~~~~~~~~ DOXNOL (5. 91) 
-==============:=:J DOX (8 . 01) 
UNKNOWN ( 11. 40) 
DOXNONE (15. 36-) DAU (14.65) 
c . I ivcr sample 
DOX (8.26) 
UNKNOWN (9.26) 
DOXNONE (15.80) 
d. aglycones and doxo rubicin in acid hydro\ ized sample 
Figure 6. The separation profiles of liver samples in a HPLC system consisted of a C-18 column 
and a mobile phase of 0.01 M phosphoric acid in 30 % acetonitrile with a flow rate 
of O. 8 ml / min 
°' N 
( 
a. 
chromatogra.l'hic 
parameter 
retention time (min) 
peak width (min) 
capacity factor (k I) 
effective plates (N) 
b. Selectivity (~) 
DOX 
DOXNCL 
DOXNONE 
DAU 
c. Resolution (R) 
DOX 
DOXNOL 
tOXNCNE 
DAU 
DOX: doxorubicin 
DOXNCL: doxoruticinol 
DOXNONE: doxorubicincne 
DAU: daunorubicin 
DOX 
8.01 
2.0 
1.26 
257 
DOX 
1.00 
1.88 
2.65 
2.49 
nox· 
o.oo 
1. 50 
4.45 
3.90 
63 
DCXNOL DOXNCNE DAU 
5.91 15.3E 14.65 
0.8 1. 3 1. 4 
0.67 3. 34 :3. 14 
873 2234 1752 
DOXNOL DCXNCNE DAU 
1.aa 2. 6 !: 2.49 
1.00 4.SE 4.69 
4.S8 1.00 1. 0 6 
4.69 1. 06 1. 00 
DOXNOL DOXNONE DAU 
1. 50 4.45 3.90 
o.oo 9.00 7.94 
9.00 0.00 0.52 
7.94 0.52 0.00 
~able 2. lhe chromatographic parameters of a EPLC system 
consisted of a .uBondapak C-18 column and a motiie phase of 
0.01M H3 PO+ in 30 ~ acetonitrile solution at a flow rate of 
0.8 ml/min. 
( 
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that retention times of doxorubicinol, doxorubicin and 
daunorubicin was 3.5, 4.7, and 8.0 minutEs respectively in 
a LiChrosort RP-8 column and a motile phase of C.01 M H3 POt 
in 31 % acetonitrile (76). Although the column used in 
this study ~as a MEondapak c-18 column, Eksborg stated that 
elution pattern was the same as for a Ef-8 cclumn and 
capacity factors were increased ty 0.2 to O.~ units on a 
log scale. In ccmpariscn with Eksborg•s data, the position 
of doxorubicinol feak was certain, the verification of 
doxorubicinone was performed ty coinjecticn of the 
hydrolyzed products of doxoruticin. 
b. The monoammonium phosphate-methanol system 
This HPLC system consisted of the same ~Eondapak C-18 
column and a motile phase of 0.01 M moncammonium phcsfhate 
solution and methanol (35:65). The chromatograms attained 
are shown in Fig. 7. The same void volume of ~.83 ml was 
used to calculate the chromatographic parameters (Tatle 3). 
Doxorubicincl was free from interferences in tbis system 
and resolution between doxorubicinone and dauncruticin was 
improved. But resolution tetween dcxoruticin and 
doxorubicinol was poor. A great disadvantage of this 
system is the low sensitivity, which was only Jt.31 ~ of 
the most sensitive one but was not too bad compa~ed with 
the mobile phase that barely separated doxcruticinol frcm 
( 
a. blank 1 iver sample 
b. spiked 1 iver sample 
UNKNOWN (8.78) 
~.----=======--- DOXNONE (9.60) 
c. 1 iver sample 
UNKNOWN (8.82) 
DOX (7. 21) 
DAU (11 .41) 
DOXNOL (6.00) 
DOX (6.9e) 
DAU (11 . 45) 
DOX (7.15) 
DOXNONE (9.62) 
d. agl ycones and doxorubicin in acid-hydrolized sample 
Figur e 7 . The chr omatogr ams of doxo r ubicin and r elated compounds in a HPLC 
system cons i sted of a C- 18 colu;nn and a mobile phase of 0 . 01 1•1 
NH
4
H
2
Po
4 
soluti on and me thanol with a flow rate of 1 . 0 ml/min 
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a. 
chromatographic 
i;arameter 
retention time (min) 
peak width (min) 
capacity factor (k ') 
effective plates (N) 
b. Selectivity (~) 
DOX 
DOXNOL 
DOXNCNE 
tAU 
c. Resolution (R) 
DOX 
DOXNOI 
DOXNCNE 
DAU 
tOX: doxoru.ticin 
DOXNOL: doxorubicinol 
DOXNCNE: doxoruticinone 
DAU: daunorubicin 
DOX 
6.98 
1. 5 
1.47 
346 
DOX 
1.00 
1.31 
1.62 
2.01 
DOX 
o.oo 
0.89 
2.38 
3.57 
66 
DOXNCL DOXNGNE DAU 
6.00 9.60 11.45 
0.7 0.7 1 
1. 12 2.39 3.04 
1176 3009 2093 
DOXNOL DCXNCNE DAU 
1. 31 1.62 2.07 
1.00 2. 13 2.71 
2.13 1. 00 1.27 
2.71 1. 2 7 1.00 
DCXNOL DCXNCNE I:AU 
0.89 2.38 3.57 
o.co 5.14 6. 40 
5.14 a.co 2.18 
6.40 2.18 o.oo 
Table 3. '.Ihe 
consisted of a 
0. 01.M NH4 H2P04 
of 1 ml/min 
chromatographic parameters of a HPIC system 
~Eondapak C-18 column and a motile phase of 
solution and methanol (35:65) at a flow rate 
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the rest in 1.a (53.26 %). 
Resolution tetween doxorubicin and doxorulicinol was 
improved by lowering the methanol fraction to O.E, as shown 
in the chromatograms in Fig. 8. Chromatographic parameters 
were calculated and showed a general imprcvement in 
selectivities and resolutions {lable 4). Simuitaneously, 
another 15 % decrease in fluorescent intensities was 
sacrificed for this improvement. Due to the great 
concentration differences between the tissue levels of 
doxorubicin and doxorubicinol, a good resolution tEtween 
these twc compounds was crucial for the accurate detection 
of doxorubicinol. As shown in Fig. 8, the very large feak 
of doxoruticin overlapped the feak of doxorubicinol to some 
degree in the mobile phase having 65 3 MeOH. 1herfore, 
this system of a MBondapak C-18 column with motile phase 
being a mixture of 0.01 M moncammanium phosphate scluticn 
and methanol (40:60) was the analysis systea cf choice for 
all ticlogical samples. 
Chromagraphic data obtained ty Strauss et El~ (37) and 
ty Haneke et al. (77) showed the conccmitant retenticn 
times of doxorubicin, doxoruticincl, doxoruticinone and 
daunorubicin in this study. A study by watscn and Chan 
(31) demonstrated the existence of an unknow aglycone and 
coincided with the peak marked •unkncwn• in Fig. 7 and 8, 
-===============---- DOX (8 . 93) 
~. blank liver sample In 65 % methanol ); ' 
~ DAU (11 •• 1) 
-.. 
f 
DAU ( 15. 31) 
DOX (7. 21 ) d. spiked liver sample In 60 % methanol 
b. spiked liver sample In 65 % methanol 
DOXNOL (]. 15) 
-c:~~~~~~~~~~~~~D~O~XN;OL (6 . 00) -----------------' DOX (9. 12) ~ UNKNOWN (10.50) DOXNONE (11.98) 
KNOWN (8.78) DOX (6.98) 
DOXNONE (9.6Q) ~===========--DAU (.15. 28) 
DOX (11.45) 
; 
c. liver sample in 65 % methanol e . liver sample in 60 % methanol 
Figure 8. The chromatograms of I Iver samples In the monoammonlum phosphate -methanol system 
°' 00 
,~ 
I 
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a. 
chrcmatcgrai:hic 
parameter 
retention time (min) 
peak width (min) 
capacity factor (k I) 
effective plates (N) 
t. Selectivity (~) 
DOX 
DOXNCL 
DOXNONE 
DAU 
c. Resolution (R) 
DOX 
DOXNOL 
DGXNCNE 
DAU 
DOX: doxcru.bicin 
DOXNOl: doxoruticlnol 
DOXNONE: doxorubici~one 
DAU: daunorubicin 
DOX 
9.12 
1.8 
2.22 
412 
DOX 
1. 00 
1. 45 
1.45 
1.98 
DOX 
0.00 
1.64 
1. 97 
3.52 
69 
DGXNOL DOXNONE DAU 
7.15 11.98 15.28 
0.6 1. 1 1. 1 
1.53 3.23 4.40 
2272 1898 1293 
I:CXNOL DCXNCNE I:AU 
1.45 1.45 1.98 
1.00 2.11 2.88 
2.11 1.00 1.36 
2.88 1.36 1.JJ 
DOXNOL DOXNCNE DAU 
1. 64 1. 9 7 3.52 
o.oo 5. 68 7.07 
5.68 0.00 2. 36 
7.07 2.36 o.oo 
Table 4. The chromatographic parameters of a EPIC system 
consisted of a ~Bondapak C-18 colum~ and a ~otile ~base of 
0.01M NH4 H2P04 solution and methanol (40:60) at a flow rate 
of 1 ml/min 
( 
( 
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of which th€ chemical structurE has yet to te defined. 
c. The normal phase system 
This HPLC system consisted of a 
chrcmatographic cartridge and a mobile phase prepared from 
chloroform, methanol, 3.0 mM magnesium chloride solution 
and glacial acetic acid (72:~1:4:3J. 1he void vclume was 
m€asured to be 1.90 ml ty injection of toluene while mobile 
phase was methylene chloride. 1he chromatograms of 
doxoruticin and its metatolite~ were shown in Fig. 9. 
Chromatographic parameters were calculated and listed in 
1able 5. 
Among these parameters, the small capacity factors cf 
doxorubicincne and daunorubicin resulted the im~ossitle 
detection of these comfounds in liver sam~les (Fig. 9). 
The resolution tetween doxorubicinone and daunorubicin was 
alsc poor. Improvements in mobile phase should le mad~ to 
overcome these shortcomings. Verification of the peak of 
doxorubicinol could te done by ccmfairing tne data frcm 
Baurain et ~1~ (40) and from Chan et El~ (46). And 
verification of doxorubicinone was done by coinjection of 
the hydrolyzed prcducts of doxorubicin. 
However, the inferiority in sensitivity and the 
( 
a. blank plasma sample 
DAU (2.81) 
1 
DOX (3.83) 
b. spiked plasma sample 
DOXNONE (2.56) DAU (2.78) 
DO X ( 3. 80) 
DOXNOL (4.79) 
c. plasma samp l e 
"'""_,;r'--:=====-- DOXNO NE ( 2. 58) 
DOX ( 3.88) 
d. aglycone and doxorubicin in acid-hydro! ized sample 
DO XNONE (2.60) 
DAU (2.80) 
DOX (3.8 5) 
e. 1 iver sample 
Figure 9. The c hromatog rams of doxorubicin and related compou nds in the normal 
phase system 
71 
( 
a. 
chromatographic 
i:arameter 
retention time (min) 
peak width (min) 
"capacity factor (k') 
effective t:la tes (N) 
t. Selectivity (~) 
DOX 
DOXNOL 
DOXNCNE 
DAU 
c. Resoluticn (R) 
DCX 
~ 
I:OXNOL 
DOXNONE 
DAU 
DOX: doxoru.ticin 
DOXNOL: doxorubicinol 
DCXNCNE: doxorubicinone 
DAU: daunoruticin 
DOX 
3.80 
0.8 
3.00 
361 
DOX 
1.00 
1.35 
2.17 
1.55 
DOX 
0.00 
1. 65 
2. 37 
1.46 
72 
DOXNOL DOXNCNE tAU 
4.79 2. 26 2. 78 
0.2 0.5 0.6 
4.04 1.38 1.93 
2294 327 3 4 :3 
DOXNOL DOXNCNE DAU 
1.35 2. 17 1. 55 
1.00 2.93 2.09 
2.93 . 1.00 1.40 
2.09 1.4C 1.00 
DOXNOL DOXNCNE DAU 
1.E5 2.37 1.46 
0.00 5.62 4.02 
5.62 o.oc 0.94 
4.02 0.94 0.00 
Table 5. ~he chromatograpnic parameters of a ncrmal t:hase 
HPLC system of a fiadial-pak E column and a motile phase of 
chloroform, methanol, 3.0 mM magnesium chloride solutiuil; 
and glacial acetic acid (72:21:4:3) at flo~ rate of 2.0 
ml/min 
( 
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employment of the hazardous, expensive chloroform made this 
system unfavorable. No specific application was suita£le 
for this system. Additionally, this normal ~base coiumn 
reguired a lengthy time, 30 minutes vs. 10 minutes cf the 
reversed phase cclumn, to eguilibrate it. ~his system, 
however, did 
existence of 
provide another 
doxorul:icino.1. 
measurement to 
The retention 
verify the 
times of 
doxorubicincl in all three systems, upon comfarison with 
those of the literature, showed similar r€sults. Although 
standard compound of doxoruticinol was unavailalle, it did 
exist in the tissue samples of rats and was atle to be 
detected by each system but with variable resolution. 
2. The Sep-pak Extraction Method 
a. Fluorescence of extracted doxoruticin and daunorubicin 
The fluorescence of doxorul:icin and daunoru~icin were 
measured after extraction from spiked ~lasma and tissue 
samples. 1he retention time of each compound remained 
consistent throughout the analysis. Calibration grafhs 
were establiihed, therefore, by the peak height ratio of 
these two compounds versus the spiked concentration of 
doxorubicin only, without the inclusion of Letertion time 
as suggested ty Hulhoven and De.sag Er (3 8) -
Figs. 10,11,12,13, were thus obtained. A~l these standard 
2 I 
0 300 600 900 1200 ISOO 1800 2100 
CONCENTRATION OF ODXORUBICIN CNG/t1l) 
Figure 10. Calibration graph for doxorubicin in human plasma 
by the organic solvent extraction method 
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Figure 11. Calibration graph for doxorubicin in human plasma 
by the Sep-pak method 
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Figure 12. Calibration graph for doxorubicin in rats' liver 
by the Sep-pak method 
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Figure 13. Calibration graph for doxorubicin in rats' kidney by 
the Sep-pak method 
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curves showed a gocd linear relationship (regression 
coefficients were greater than 0.98) betweeD FEak heights 
ratios and concentrations of doxoru~icin. 
All sample injection was performed ty the auto~atic 
sample frccessor (WISP, Waters) and the 
determinaticn was calculated as peak height 
9uantitative 
l:;y the data 
acquisition system (Data Module, Waters). The coufling cf 
these two instrument~ and the fl~orescent detector was 
tested for its accuracy and sensitivity. lhe sensitivity 
varied with the mobile phase and chromatographic coiumn 
used in the analysis. The lowest limit of sensitivity for 
doxorubicin was 5 ng/ml for tbe chrcmatographic conditicns 
specified iD Figs. 10,11, and 15 ng/mi for those specified 
in Figs. 12,13. !he accuracy was determined l::y three 
repeated injections of an appropriate samFle at 5, 10, 20, 
25, 40, 50, 70, 100, 150, 180, 200 .ul respectively and the 
coefficient of variation was · an average of 6.1~0.4 ~-
1he addition of the internal standard, daunoruticin 
before extraction or homogenization was to ccaEensate for 
the differences in matrix and sample volume. In addition, 
the corresfcnding changes in daunorubicin concentrations 
allowed the detection of the wide physiological raLge of 
doxorub_icin levels ( 10-1,000 ng/ml) i.n plasllia samples 
(15,23,25,31,44,73-75). A wider concentration difference 
( 
79 
was ctserved between the levels of doxorubicin (the highest 
could be 4C ~g/Gm) and those of its metatolites (the lowest 
could be 50 ng/Gm) in tissue sam~les (18,78-80). And the 
simultaneous detecticn of these compounds in tissues made 
the adjustment of daunorubicin concentration unfeasitle. A 
solution was suggested to make separate assays fer 
doxorubicin and its metatolites, each sam~le with an 
appro~riate weight of tissue. This would te feasitle since 
extraction procedure was not affected by changes in tissue 
weight in the range tetween 100 400 mg and ccm~lcte 
homoginization was assured (Tatle 6). Besi3es, this 
alteration would be adventaqeous to 
self-aggregation phenomenon of doxoruticin, 
tc form 
avoid the 
~articularly 
dimer at 0.5 dimerizaticn. Doxorubicin begins 
~g/ml and this phenomenon can 
than 10 % of the fluorescent 
significantly reduce more 
intensities when the 
concentrations are more than 5 ~g/ml (47). 
Although peak height ratios showed small variation 
(smaller than 10 %) in the calibration curves, these were 
performed with only one sample per concentration of 
doxorubicin (Appendix). Variation in peak height ratios 
was tested again with 6 samples per concentration as shown 
in 1able 7. 1hese results also showed coefficients of 
variation to be smaller than 10 3 and demonstrated that the 
Sep-pak method was accurate and precise for doxorubicin 
( 
l 
tissue . h * 1,.2. 3 weig t peak height ratio coefficient of 
(mg) variation 
liver 102.4_:!5.3 0.5732_:!0.010ti 1. 82 
liver 372.2!_1. 1 0.5762!_0.0295 5.12 
kidney 98.5!_4.3 0.6166!_0.0025 0.40 
kidney 388.2!_9.4 0.6034!_0.0133 2.20 
*1 ~issue were from one rat of unknown age whose tissues 
served as blank in this study 
*2 The results of each tissue weight group were attained 
by the assays of three spiked tissue samfles 
*3 Spiked concentraticns cf doxorubicin and daunoruticin 
were 500 ng and 100 ng fer sample respectively 
80 
Table 6. The relatioushiF between tissue weight and feak height 
ratio 
*' .2 Sep-pak processed standard solution *4 sample · 
(DCX/DAU) plasma sample 
•3 
peak height ratio c.v. peak beig.ht ratio c. v. 
30/200 0.0226_:!:0.0114 5.10 0.2313_:!:0.0114 4.93 
100/200 0.6819_:!:0.0064 0.94 0.6792_:!:0.0280 4. 14 
300/200 1.8870,:t0.0202 1.07 2.0844_:!:0. 137~ -6.58 
700/800 4.6778,:t0.0543 1. 16 4.7059_:!:0.0850 1. 81 
*1 samples are expressed as the concentration cf doxorubicin 
(DOX) and daunorubicin (DAU) in ng/ml 
*2 1he results in each concentration group were obtained ty 
6 spiked samples 
*3 c.v. is the abbreviation of coefficient of variation 
*4 Standard solution was referred to DOX and DAU in motile 
phase 1 
81 
Table 7. Comparison of the variation tetween Sep-Fak procEssed 
samples and standard solutions 
( 
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analysis. Similar results of this test of variaticn among 
tissue samples were also observed in Tatle 6. 
b. Recovery rates and silanization 
1he standard addition method was first used to 
calculate the recovery rates and a typical result of spiked 
samples was shown in Tacle 8. Two unusual phenomena were 
observed; one was that apparently greater than 100 % of 
the spiked amount was recovered and the other was that 
there was a large variation within an individual sample. 
in order to determine the causes of these phenomena, 
control groups were assayed and calculated. Tbe results 
shown in Table 9 demonstrated that even standard solutions 
of mobile phase and of the acid-methanol mixture suffered 
these flaws. From this compariscn, Sep-pak methpd was 
definitely not the cause . and, instead, the calculation by 
the standard addition method was suspected to te the cause. 
Therefore, the direct method and the elution method were 
used as different approaches to calculate recovery rates 
(Table 10) • 
Results in Table 10 showed vivid dif ferencEs in 
recovery rates calculated by tbese three methods. ~ith the 
silanized glassware, the recovery rates calculated ty the 
standard addition method, the direct methcd and the elution 
( sample* peak height c. v. of Recovery c. v. of (DOX/DAU) ratio ratio rates recovery 
30/800 0.3798 8.94 122.8 10.91 
_:t0.0339 _±13.4 
50/800 0.€426 3.14 166. 4 13.60 
_:t0.0202 16. 6 
70/800 0.8919 9.29 122. 3 6.72 
_:t0.0829 _:t8.2 
200/800 1.5885 6.79 106.1 20. 17 
_:t0.1079 .!21. 4 
400;800 3.2367 4.86 122.1 52.04 
_:tO. 1574 _:t63.6 
600/800 5. 9501 1. 74 114. 3 5.30 
_:t0.1034 _:t6.0 
800/800 6.4997 0.44 182.6 a.so 
_!O. 0283 _:t0.9 
1000/800 8.7547 3.12 185. 9 18.64 
_:t0.2728 _:t34. 65 
1200/800 9.9112 1.; 92 166.01 28.66 
_:tl.1900 _:t47.6 
1400/800 12.6124 2.37 135.E 4.98 
_:t0.2991 _:t6.8 
1600/800 13.9111 5.55 271. 1 105.27 
_:t0.7718 ±285.4 
2000/800 15.5264 4.54 98.5 8.65 
_!0.7048 _:t8.51 
* The results in each sample group were obtained from one 
sample ty three determinations 
Table 8. 1he peak height ratios and recovery rates of 
spiked kidney sam~les 
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concentration~ 1 type of sample 
of doxorubicin mobile •:i phase acid-methanol Sep-i:ak processed 
(ng/ml) mixture 113 solution *3 
30 130. 4± 9.3 127.8!: 8. 3 130.6±18.8 
100 151. 2± 1 o. 4 122.7±27.7 117.1±50.8 
300 97. 8_! 2. 8 13~.8± 3.3 111.9±14.9 
700 130. 5_!53.9 11o.2± 15. 3 94.2!33.7 
*1 The result in each sample group was obtained from three 
spiked samples 
*2 Mobile phase is consisted of 0.01 M ~hosphoric acid in 
32 ' acetonitrile _3 
*3 Acid-methanol mixture is the eluent, 5.0X10 M phosphoric 
acid in methanol, used in the Sep-pak method 
*4 Sep-pak processed solution is prepared from the addition 
of standard compounds into the concentrated eluent of 
blank plasma by the Sep-pak method 
Table 9. The recovery rates of different types of samplEs. 
( 
'1f l, .2 
sample standard addition direct method elution 
method methcd 
~ 
silanized non- silanized non- silanized 
silanized silanized 
organic extraction method 
plasma - - 88.6 54.8 -
.:!: 10. 9 .:!: E. 4 
Sep-pak method 
plasma 113.7 83.0 107.2 86.1 102.2 
±22. 7 ±14.9 _:!:7. 0 _:!:4.0 _±5. 6 
liver 120.5 72.8 188.9 83.0 99.4 
_:!:27. 7 .:!: 14. 5 _:!:6. 5 _:!:2. 1 .±2. 1 
kidney 122.1 68. 5 158.7 78.0 98.6 
_±23. 2 .:!: 15.1 _±6.3 .:!: 1. 3 _±4. 3 
lung 129.7 - 201.1 - 96.4 
±27. 2 _:!:5.5 _±7. 2 
heart 112.6 - 217.2 89.7 92.4 
_±21.4 _±4.8 _±6.5 .:!: 5. 8 
mean 119.7 74.8 178.6 84.2 97.8 
_±STD _:!:21. 7 _:!:17. 4 _!:39. 3 _±5.6 _±5. 8 
ave. * 3 21.9 3.9 5.4 
STD 
*1 Results in each group were obtained by three spiked samples 
*2 Spiked concentrations of doxorubicin and daunoruticin were 
500 ng and 1000 ng FEr sample respectively 
*3 Ave.STD represents the averaged standard deviation of each 
method 
Table 10. The recovery rates of spiked biological samples 
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method were 178.6!39.3 and 97.8!5.8 
respEctively. lhe results calculated by the standard 
addition method were not convincing due to the high 
variation (coefficient of variation averaged 18 3). The 
high reccvery rates (averaged 178.6 '> that calculated by 
the direct methcd arose from the high fluorescent tlanks in 
tissue samples. 1he high variation in recovery rates (39 
'> calculated by the direct method was caused by the lower 
fluorescent backgrcund that was ctserved alone in the 
plasma samples. 1he fluorescent absorbances of tlank 
samples of tissues were shown to te twice as high as that 
of plasma blank. The exclusion of internal standard during 
extraction (see Methodology) left the high fluorescent 
tackground in tissue samples uncorrected and the degr~e of 
fluorescent contribution varied. 
The elution method, then, seemed to be the cnly method 
that reflected the true recovery rates of th€ extraction 
procedure. This method was similar to the direct metncd 
but did not show a high fluorescent tackgrcund due to the 
dilution ef£ect of the large volume of the eluent (7 ml). 
The slightly lower recovery rates observed in heart and 
lung samples were probably attributed to the difficulties 
in homogenizing these tissues. 1he only disadvantage in 
using the elution method was the difficulties in 
determining the extractiqn efficiency of samples s~iked 
( 
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with low doxorubicin concentration. However, all three 
methods sho~ed little er no variation when the spiked 
amount of doxoruticin changed. 
lhe high variation in recovery rates that only 
observed in the standard addition method were the result of 
compounded variation in calculation. lhe peak heights of 
doxorubicin and daunorubicin were subjected to a 
6.1~0.4 % 
by each 
According to the 
method (see 
coefficient of variation of 
calculation eguations used 
Methodology), the standard addition method may have a 
compcunded variation of 36 % while the other two method 
have only cne single 
agreed very well with 
variation. The Iesults in 1atle 10 
the predicted values, i.e., the 
coefficient of variation was an average of 21.9 % in the 
standard addition method, 3.9 % in the direct method and 
5.4 ~ in the elution method respectively. 
Silani2ation played an im~ortant role during 
doxcrubicin extraction. ·1able 10 revealed that at l€ast 
25% of the doxorubicin was lost to the glass wall and that 
dimethyldichlorosilane 
adsorption phenoaenon. 
could effectively prevent this 
( 
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c. Com~arison with other methods 
lhe recovery rates for organic extraction method were 
lower than those of the Sep-pak method, regardless of the 
calculation methods used. The Sep-pak method is definetely 
superior to the organic extraction method in the ease of 
operation, the required time for processing, and 
efficiency. Factors such as pH of the aqueous phasE, the 
volume ratio between organic and aqueous phases, the mixing 
time and separating of phases that should le carefully 
controlled to obtain maximal efficiency - in the organic 
extraction method were aisregarded in the Sep-~ak method. 
lhe Sep-pak method required only a Sep-pak cartridage and 
an a~propriate solvent for the elution of doxorubiciL and 
related compounds. It also eliminated the consum~ticn of 
the hazardous chloroform and reduced the prccEssing time 
from 30 minutes to 1 minute ~er sam~le. 
The hydrolysis of doxoruhicin which may l::e caused by 
the strong acidity {pH=2~34) of the acid-methanol mixture 
could by prevented by adjusting the pH to 4 5. The 
addition of two drops of 20 % NaCH in methanol right after 
elution from the Sep-pak cartridge were enough tc prevent 
the hydrolytic reaction while 5.2 % of doxorutici~ iL the 
control group were hydrolyzed to doxorubicinone. Thus, the 
hydrolysis of doxorul::icin was influenced l:y pH and nEeded 
( 
( 
incubation time 
disadvantage in 
to 
the 
proceed 
Sep-pak 
hydrolysis. 
method was 
1he 
that 
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only 
Sep-pa k 
cartridge could net te re- used and a reduction of more than 
10% in efficiency was observed in the second u~e. Except 
this shortcoming, Sep-pak method provides a fast, easy, 
efficient and convenient way for sample preparation. 
Since the extraction efficiency for tissue samples was 
dependent en a ccmplete extraction from the cellular 
components, reagents such as silver nitrate, sodium lauryl 
sulfate and phosphate tufter were investigated fer the most 
efficient conditicns. The results of these trials are 
shown in Table 11. Schwartz proposed the use of 0.1 % 
sodium laur1l sulfate sclution which facilitated tbE cell 
lysis and thereby maximize doxoru~icin extraction (39) • 
But sodium lauryl sulfate solution failed to te helpful in 
this study. 1he pH 7.4 phosphate tuffer proposed by 
Johansen was not efficient (32.4 vs. 83.0 %) when coupled 
with the S~p-pak method (72). Besides, the phosphate 
tuffer method showed a higher degree of interferences in 
the blank samples as shown in Fig. 14. Therefore, the use 
of ~O ~ silver nitrate solution alone was demonstrated to 
be the method of choice with respect to both efficiency and 
resolution. 
It should be noted that the difference in reak h~ight 
( 
.ifl 
method peak height apparent percEntage 
ratio of recovery by the 
direct method 
33~ AgN03 1.0368 61.8 
0.1% SLS'° !0.0176_:!:1.6 
33% Ag NO~ 1.1020 6~.7 
!0.0183_:!:1.1 
50% AgN03 1.2875 76.8 
0.1% SLS _:!:0.0351!2-1 
50% AgNC3 1.3917 83.0 
!0.0344!2-1 
~H 7_4•3 0.5432 32.4 
l:uf fer _:!:0.0219!1. 3 
*1 Ihis method is the homogenization of 3 spiked liver 
samples with the reagents indicated and with 
non-silanized glassware 
*2 SLS is the abbreviation of sodium lauryl sulfate 
solution 
*3 Ihis buffer is the phosphate buffer of pE 7.4 
Iable 11. The recovery rates of spiked liver samples by 
dif fErent methods · 
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~ 
a . blank liver sample by phosphate buffer method c. blank liver sample by silver nitrate method 
t 
~~~~~~~~~~~~~~~~~DOX(B.10) · ~ DOX(B.13) 
,f: ~ o DAU (14. 71) i •DAU(l4.65)oF 
-b. spiked liver sample by phosphate buffer method d. spiked liver sample by silver nitrate method 
method 
Vi rrure l~. The chromatograras of liver ~a11~le~ processed by the phos~hate oufrer anc the silver nitrate 
"'cthods. '1'111' 1-tPLC sy,-tem consisted of a C-18 colui1111 rn1u ri 1110Lilc phase of 0.01 M H
3
Po
4 
in 
lO ~ aceto~itrlle with n flow ~ate of u.B ml/ruin. · ~ 
....... 
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ratios between adding daunorubicin in the teginning and 
after the extracticn process {homogenization and Sep-pa k 
method) was sho~n to be almost two-fold. 1his phenomenon, 
however, did not exist for plasma samples. 1he dirferent 
extraction efficiencies of daunorubicin tetween plasma and 
tissue samples indicated that although Sep-pak cartridge 
had the same efficiency toward both doxorubicin and 
daunorubicin, almost half of the daunorubicin was not 
extracted by the homogenrzation step. 1his loss of 
daunorubicin suggested that daunorubicin may not te the 
internal standard of choice for doxorubicin extracticn from 
tissue, despite the fact that structural difference tetween 
these two compounds is only one hydroxyl group. This 
coincides with the very phencmenon also 
phamacokinetic and pharmacological properties 
doxorubicin and daunoruticin. 
different 
tetween 
I 
( 
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B. Fharmacokinetic Studies 
1. Plasma Samples 
Plasma samples from four patients were assayed and the 
results are shown in Figs. 15,16. Doxoruticin levels in 
J.C. and M.C. were measured by the organic ext~action 
method while those of the J.M. and A.O. were measured 
following the Sep-pak approach. Pharmacokinetic 
parameters, ex , /3 , initial concentration (Co) and 
micro-constants such as rate constants -0£ distribution 
between the first · (central) and the seccnd ccmpartments 
(K12 and K21 ) and rate constant of elimination (KeL), were 
calculated by AUTCAN. These parameters are listed in 
Table 12 and the smooth curves in Figs 15,16 represented 
the simulated plasma levels. 
The pharmacokinetic profiles of all four patients' 
data could be ex~ressed by the two compartment model. 1he 
initial concentration (C 0 ) and the volume of distribution 
were in a good agreement with the assay methods. These two 
groups cf samples, organic extraction methcd versus Se~-pak 
method, were processed separately and these sam~les arrived 
at different time. Other than this, the ~, ~, half-lives 
and micro-constants all showed 
remarkable agreement. The low regression coefficient (E) , 
( 
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patient M.D J.C. A.D J.M. 
dose (mg) 90 60 64 60 
age and sex F-61 F-72 F-48 M-68 
disease cervical endometrial colon me.sothalial 
status carcinoma carconoma carcinoma carcinoma 
r sguare 0.9981 0.9505 0.9982 0.8447 
alpha (hr-' ) 5.1506 4.9596 6. 0842 4. 8 380 
beta (hr-' ) 0.0769 0.1210 o. 1008 0.1792 
t~ (alpha) o. 134 0.140 0. 114 0.143 
(hr) {min) rn.:J.> (..§~) (6. 8) (.§.:..§) 
t~ (l:eta) 9.01 5.73 6.88 3.83 
(hrs) 
Co (ng/ml) 7406 4024 1216 943 
Vd (liters) 12. 15 14.91 52.61 63. 61 
K,2 (hr -· ) 3.8305 4.4985 4.0320 2.0766 
K.l, (hr_, ) 0.4538 0.3262 0.3168 1.1225 
KEL (hr _, ) 0.8901 1.1362 1.6808 1. 0759 
Table 12. The pharmacokinetic parameters concerning tbE: pl asma 
samples of four cancer patients 
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and the large deviation in ~, a and micro-constants in J.M. 
were the results of missing data between 1.0 and 12.0 hours 
after the administration of doxorubicin. Insufficient 
volume, less than 0.3 ml, of these samples fail€d thE 
detection limit of 15 ng/sample specified in the HPLC 
system and therefore made the guantification im~ossitlE. 
lhe initial concentrations of doxorubicin were in 
agreement with those of the liteiature, which bad Co 
l:etween 1-5 .«g/ml (15,44,45, 79,80). Only Lee et al.!.. 
reported initial concentrations after a single talus i.v. 
of the usual dosage (40-60 mg/m~) to be around 10 Mg/ml 
(81). No data fiom the literature concerning the volume of 
distribution were available, due to the re~crted total 
dosages, for com~arison. The half-lives calculated from 
and also showed similar values as those of the 
literature (15,23,25,31,44,73-75). The calculated value of 
the .half-li'fe of o(. phase ¥as 8. 0 versus 10 minutes of the 
literature and that of the half-life of ~ phase was 6.4 
hours in this study versus 10 hours in the literature. The 
large variation in volume of distritution, however, was 
unaccountable. From Table 12, it was observed that the 
youngest patient (A. D.) did exhibit faster rates for toth 
distribution and elimination. Its sig~ificance was hard to 
determine since no other young patients were included in 
this study. Ihe sex and disease status did not have 
98 
significant effects in this study. Metabolites ~ere not 
detected in any of these four fatiEnts. 
Data from rat plasma were also analyzed ty AU~GAN and 
depicted in Fig. 17. to show both the observed ~nd the 
predfcted values. Pharmacokinetic parameters were also 
calculated and listed in Table 13. DUE to the missing 
information of total doses, the volumes of aistritution 
were unable to calculate and thereby missing fro~ this 
table. 
Pharmacokinetic parameters such as ~, ~, 
C 0 and micro-constants did show a higher 
half-livEs, 
degrEE of 
variation than those of human ~lasma samples. 
Statistically, only group B was different from the rest. A 
closer observaticn revealed that the aged groups (C and D) 
showed higher rate constants of elimination and highEr 
initial concentrations. This observation did net correlate 
with the physiolcgical conditions of the aged, which 
usually sho~ a slow distribution fhase that leads to higher 
initial concentrations and a slow elimination ~hase that 
leads to lower elimination rates. However, t-test was not 
perfcrmed due to the insufficient samples in cact grcu~ 
(n= 2) • 
lhe diff iculitie$ in interpreting the effects of age 
( 
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l~ ig ure 17. Plasma levels of doxorubicin in rats; the young groups 
were A(.,--) and B( '" , ---), and the old groups were 
C(o,-----} and D(L>,-·-). The smooth curves are the 
simulated data by a two-compartment model. 
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group A B c D 
age 2 months 2 months 2 years 2 y€ars 
r square 0.9987 0.775 o. 9326 1.000 
alpha(hr- • ) 1.2374 0.0062 0.2476 0.0319 
beta (hr-' ) 0.0220 0.2800 1.20t0 1.3392 
tt_ (alpha) (hrs) 0.56 2.48 0.57 0. 5.2 
t~ (be ta) (hrs) 31. 51 111.80 14.Sc 21.75 
Co ( ng. ml) 798 584 3185 1299 
K '' 
(hr _, ) 0.8595 0.1804 1. 040 3 0.9487 
K.z1 (hr_, ) 0.2825 0.0357 o. 40 48 0.2552 
Kn (hr _, ) 0.0962 0.0417 0.3189 0.1673 
Table 13. The pharmacokinetic parameter concerning the plasma 
samples of rats 
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on doxorubicin pharmacokinetics was partly due tc thE small 
sample size and partly due to the poorly defined age 
groups. The age group£ of 2 ~onths and 2 years seerued to 
fall, respectively, in the very young and the very old 
parts of the life span of rats. ~here were no central 
groups 'of medium age) for this study. Since tbe very 
young specits have .similar physiological abnormalities as 
those of the very old sp~cies, such as decreased frotein 
binding, decreased volume of distribution, a higher fat 
content, reduced metabolism, etc. 
necessarily see much differences 
groups. 
(59,69-71). One may not 
between these two age 
From Fig. 17, a comparison with the literatur€ data 
was made. The observed doxorubicin levels iE rat plasma 
were significantly lower than those reported ty Maratino ~! 
al., Sonneveld et al. and ozaols et al~ (16,79,82) but were 
in good agreement with those of Johansen, Broggini et al~ 
and Pacciarini et E~ (72,83,84) 'The plasma samples of rats 
also exhitited two metabolites; doxorubicinol and 
doxorubicinone, and their concentrations as doxoruticin 
equivalents were listed in 1able 14. 
appeared in the bloodstream almost 
doxorubicin itself as shown in 
Tbese metabolites 
simultaneously 
Figs. 18-21. 
with 
Tb is 
phencmenon was also cbserved in the plasma samples of human 
and rabbits, which was attrituted to metabolism cccurred in 
( 
group t. *' ' i.me doxorubicin doxorubicinol doxorul:icinone 
of (hours) concentration concentration concentration 
rats (ng/ml) (ng/ml) ·~ (Dg/nl)* 2 
A o. 5 512. 2.:.!: 20.4 492.1!:70.9 202.0.:,!:47.4 
1. 5 267.2!: 21.0 339.5.:,!:46.2 163.2.:,!:12.0 
4.0 171. 3.:.!: 9.4 183.0!:19.6 o.o 
10.0 128.6.:.!: 5.2 87.5!:17.9 35.7.:.!: 3.0 
24.0 103.2.:.!: 18.2 80. 7!: 1. E 101. 7±22. 7 
50.0 58. 6!: 11.2 122.8.:,!:25.8 0.0 
B 0.5 548.6.:.!: 25 • .£ 151.2.:,!:18.6 0.0 
1. 5 37 3. 6!: 12.2 131.2.:,!:20.1 0.0 
4.0 28 7. 7.:.!: 56.5 103. 7!:19.6 o.o 
10.0 99.2.:!: 11.0 64.2!:14.7 a.a 
24.0 62. 6.:!: 9.7 21. 6_:!: 5.2 o.o 
50.0 53. 3.:!: 12.5 53.3.:!: 1.7 a.o 
c 0.5 1641. 7± 28.5 123.9_:!:12.1 a.a 
1. 5 811. 1.:.!: 42.8 69.0!:15.8 0.0 
4.0 763.6_:!:103.8 104.6_:!:17.2 0.0 
10.0 213. 6.:.!: 2 1. 3 41. 8.:!: 6. 1 a.o 
24.0 96.2.:.!: 0.2 53.5_:!:12. 7 o.o 
50.0 60. 7±13.6 o.o o.o 
D 0.5 770. 2.:.!: 6.8 o.o a.o 
1. 5 356.2.:!: 6.7 78.5~15.8 o.o 
10.0 161. 4!: 21.0 52. O.:.!: 4.8 0.0 
50.0 45. 1.:!: 8.9 o.o 0.0 
*1 The results shown at each time interval in each 
group were attained ty repeated assays of three 
samples fro~ one rat. 
*2 The concentrations of metabolites(doxoruticinol and 
doxorubicinone) are ex~ressed as the doxoruticin 
equi val en ts. 
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Table 14. levels of doxorubicin and its metabolites in rats• 
plasma ty the Sep-pak method 
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Figure 18. Plasma levels of doxorubicin (., --) , doxorubicinol ("' , ---) 
and doxorubicinone (o,---) in group A rats. 
Concentrations of the metabolites are expressed as doxorubicin 
equivalents. 
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Figure 19. Plasma levels of doxorubicin (., --) and doxorubicinol 
( 0" , ---) in group Brats. 
Concentrations of doxorubicinol are expressed as 
doxorubicin eq uivalents. 
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Fugure 20 . Plasma l evles of doxorubicin ( ., ~- ) and aoxorubicinol 
c~ , --- ) in group c rats . 
Concentrations of doxorubicinol are expressed as 
doxoru~icin equiva l ents . 
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Figure 21. Plasma levels of doxorubicin (., ~-) and doxorubicinol 
( 0'' , ---) in group D rats. 
Concentrations of doxorubicinol are expressed as 
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the tloodstream (15,44,45,85). Doxorubicinol levels in rat 
plasma did not 
young and old 
show significant difference tetween the 
rats. Only 
different from the rest. 
group 
This 
A was statistically 
observation did not 
correspond with that of doxoruticin levels in which grcup B 
was significantly different. 
Therefore, this study did net reveal the ~ossitle 
roles of age in doxorubicin ~harmacokinetics. ~he 
difficulties in analyzing the data from rat plasma arose 
from the small sample size of each group and the lacking of 
contrcl groups. 
2. Tissue Samples 
Kidney samples of four groups of rats were assayed and 
the results shown in Table 15. A higher variation was 
observed when concentrations of doxoruticin or 
doxorubicinol fell below 5 Mg/Gm cf tissue. This was due 
to the detection limit of the HPLC system which, as 
mentioned before, could not tolerate the signal to noise 
ratios to fall below 5. 
As shown in Fig. 22, there was a 40-fold difference 
tetween the concentrations of doxorubicin and 
doxorubicinol. And the only possible way fer accurate 
\ 
time .. , DOX * 4 *.3 DO.X NOL•+ group c.v. c.v. 
of (hrs) cone. cone. 
rats (n g/Gm) (ng/Gm) 
A 0.5 3.57_:!:0.66 18. 37 0.0 -
1. 5 42. 44_:!:6.67 15.71 1. 13,:!: 0. 27 23.77 
4.0 15.20,:!:1.60 10.54 o. 29±0- 07 25.38 
10.0 14.11,:!:0.70 4.96 0.25_:!:0.03 13.60 
24.0 9.89_:!:0.98 9.91 0.16,:!:0.01 8.63 
50.0 14.58_:!:1.39 9.56 0.47,:!:0.03 6.56 
B 0.5 16.89±0.34 2.04 o.o -
1. 5 17.27,:!:0.74 4.28 0.15_:!:0. 04 23.31 
4.0 18.50,:!:0.19 1. 03 0.12_±0. 03 22.15 
10. 0 16.48_:!:1.47 8. 91 o. 24,:!:0- 05 19.94 
24.00 16.94,:!:1.24 1.30 0.52±0.09 17.10 
50.0 7.74,:!:0.66 8.53 0.34_±0.05 15.88 
c 0.5 28.84_:!:1.79 6.21 o. 64_:!:0. 11 17.66 
1.5 17. 3 3± 1. 2 0 6.92 0.95_:!:0.13 13.60 
4.0 21.48_:!:2.44 11.34 o. 80,:!:0- 10 12.10 
10.0 34.44,:!:6.55 19. 03 0.78_±0.14 18.53 
24.0 25.46,:!:5.26 20.66 o. 79,:!:0. 15 19.47 
50.0 16.07_:!:0.37 2.29 0.89_:!:0.12 13.54 
D 0.5 20.66±4-22 20.43 0.08_:!:0.01 14.40 
1.5 36.87,:!:6.46 17.52 0.85±0-14 15.90 
10.0 17.83_:!:0.26 1. 4 7 0.46,:!:0.07 15.54 
50.0 12. 02,:!:0. 52 4.31 0.43_±0. 10 22.64 
~ 
*1 The results shown at each time interval in each group 
were obtained from re~eated assayed of three sam~les 
from one rat. 
*2 DOX cone. = doxorubicin concentration 
*3 c.v. = coefficient of variation 
*4 DOXNOL cone. = doxcrubicinol concentration expressed 
as doxoruticin eguival~nt 
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Table 15. The levelE of do~oruticin and doxorubicinol in rats• 
kidney 
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Figure 22. Kidney l eve l s of doxorubicin (., ~-) and doxorubicinol 
(":, --- ) in group A rats. 
Concentrations of doxorubicinol are expressed as 
doxorubicin eq uivalent s . 
109 
( 
{ 
( 
110 
quantification of both compounds was the se~arate analyses, 
as suggested before. Many articles ignored the metabolites 
in rat tissue samples claiming their amounts were 
insignificant (18,54,72,79) while ether reported high 
fractions {upto 40 ~) of the total doxorubicin equivalents 
in tissue were the metabolites (78;86). Although the 
cbserved results shown in Table 15 coincided with the 
former, further studies in other tissues such as heart, 
liver, lung, spleen, train, etc., should te engaged to 
confirm the common existance of this phenomenon. If this 
holds true for all tissue, it would not te worthwbile tc 
carry out another analysis tc guantitate such a mimer 
component. 
The kidney levels of doxorubicin were only half of 
those re~orted in the literature (16,72,83). 1his was due 
to inaccurate determination of internal standard whose 
signal to noise ratio was lower than 5. This was 
unavoidable since only one concentration of daunorubicin 
solution was used. However, these errors occurred cnly for 
a few samples when doxorubicin concentrations exceeded 20 
og/Gm of tissue. Since the quantifies of kidney 
metabolites were determined as minor components, future 
assays of tissue samples should be carried out with a 
smaller sample size and an appropriate concentration of 
daunorubicin to cover the range of 8-40 ~g/Gm of tissue. 
( 
1 1 1 
The smaller sample size of tissue is also encouraged by the 
fact that the self-aggregation. if happens above 5 ~g/ml. 
will significantly reduce the fluorescent intensity of 
doxorubicin (47). 
A graph of doxorubicin levels in all four groups of 
rats revealed the same difficulties in recognizing the agE 
effects (Fig. 23). As discussed previously, the small 
sample size and the lacking of control groups were the 
causes. 
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Figure 23. Kidney levels of doxorubicin in rats. 
Groups A (., --) and B ("<, --- ) were the 
young rats, and groups C (c, --·-) and D 
( .::i. , - · - ) were the o l d r a ts . 
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c. 1be Stability Study 
1. 1he StaLility cf Doxorubicin in Solution 
Rates of doxoruticin degradation at various 
concentrations were first guantified and they were shown to 
be the same. Therefore, a first order degradation process 
was assumed. A semi-log plotting procedure was applied to 
these data and the superimposed straight lines confirmed 
that the degradation process of doxorubicin was a first 
order reaction. The stability evalution was then performed 
with buffers of various pHs, different buffering systems, 
water, acid-methanol mixture and mobile phase of thE 
analysis system (0.01 M monoamonium phosphate solution and 
methanol (40:60)). 1hese rate constants as well as the 
T~'s, expressed in either hours or days, were listed in 
1able 16. 
The Tqo would be a more suitatle parameter to evaluate 
the degradation than the conventional T50 • Eecause 
indicated the time when only 10 % of doxorubicin in 
solution has degraded rather than 50 %. This criterion is 
the maximal time ~eriod for doxorubicin soluticn to exhibit 
acceptable stability since this antineoplastic ~gEnt bas 
such a small therapeutic index (87). 
medium rate constant T'° (hr·• ) "llours aays 
PCB*' pH 2.00 2.16x10·+ 487.8 20.3 
PCB pH 3.00 1.11x10·+ 494.2 39.5 
PCB pB 4.00 1.20x10·-t 823.1 34. 3 
PCB pH 5.00 2. OOX 10·4 526.8 22.0 
PCB pH 6.00 3. 1-6x 10·4 280.2 11.7 
PCB pH 7.00 5~63x10·+ 187 .1 7.8 
PCB pB 0.00 1.41x10·3 74.7 3.1 
PCB ph10.00 2. 38X 10 -a 4.43 -
-, 
PCB pH11.00 5. 65X 10 ·a 1. 86 -
PCB .pH11.90 0.129 0.82 -
P-B*2 pH 7.40 1. 85X1 o ·.a 5.70 -
P-B pB 7.00 1. 18X 10 ·a 8.93 -
1-!(3 pH 2.34 0~91x10·& 1174.8 48.95 
H.aO pH- 5.62 1. 82X 1 o ·4- 585.3 24.39 
.... M.P. pH 4.00 8.32X 10-5 1266.6 52.77 
*1 PCB is the buffering system consisted of phos~hate, 
citrate and borate 
•2 P-B is the phosphate buffer 
•3 A-M is the acid methanol mixture used in Sep-~ak 
extraction method 
•4 M.P. is the mobile phase used in the HPLC analysis 
system 
Table 16. The rate constants of doxorubicin degradation in 
various media 
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From 1able 16, it is observed that a change not only 
in pH but also in the tuffering agents shewed a difLerent 
rate of degradation. However, pH did not have a 
significant effect on degradation once it dropped telow 
5.00. 1he variation in these rate constants (pE ~ 5.00) was 
thought to te a deviation from a true value rather than the 
effects cf fH. 
A graph of the rate constants in the same tuf fer 
system (the citrate phosphate borate tuffers) 
explicitly demonstrated the effect of pH on doxoruticin 
stability (Fig. 24). 1his graph showed that the rate 
constants dropped sharply around pH 11 and doxorubicin was 
stable in a pH range of 2.0 to 7.0. 1his phenomenon 
justified the raising pH of eluents to only 5-6 in the 
Sep-pak method and the neutralization of ultrafiltrates in 
the protein binding study. 
The tuffering agents also demonstrated a significant 
effect on doxorubicin degradation. The rate constants of 
soluticns of the same pH 7.00 were S.36x10 -+ hr for 
phosphate-citrate-torate tuffer and 1.18x1o-~ 
phosphate tuffer. Such a wide difference in 
hr for 
stability 
cautioned the choice 
fluid when long i.v. 
to be the route of 
of storage medium or the infusion 
infusion (upto 96 hours) was chosen 
administration (88) • A graph of the 
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Figure 24. The effect of pf-f on doxorubicin stability in the 
citrate-phosphate-borate buffer system 
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rate constants, expressed as the percentage of doxorubicin 
remaining, clearly showed the effects of pE and tuffering 
agents (Fig. 25). And the advised storage tine cf Tq0 
could be determined by the points the intercept of an 
abscissa of 90 %. 
The degradation products of doxorubicin hydrochloride 
have not yet been identified. Since they did not show any 
chromatographic peaks in any of the three HEIC systems 
used, they possessed little, it any, fluorescent 
properties. Ther~fore, it was impossible tc postulate the 
iossible degradation products from doxorubicin ionization 
in which the icnized 
properties (Fig. 4). 
species all have 
2. ihe Stability of Doxorubicin in Elasma 
fluorescent 
!he coLcentration of doxorubicin in spiked frozen 
plasma samples decreased during storage. This degradation 
was further aggravated by the number of freezing/thawing 
cycles (!able 17). Frozen plasma samples, thawed at the 
intervals of 0, 1, 3, 5 days respectively, were extracted 
using the Sep-pak method and analyzed chrcmatographically. 
While samples experienced a loss of 40 % after 10 
freezing/thawing cycles, the contrcl groups lest only 3.9 
~. 15.2 %, 29.2 % of the original doxoruticin. An 
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Figure 25. The effects of pH and buffering agent~ on doxorubicin 
stability. P.B. stands for phosphate buffer and the 
unspecified buffers were of the citrate-phosphate-
borate buffer system. 
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doxorubicin ~ of DCX sample group thawinq/freezin9 
cycles concent:raticn :remaining 
(ng/ml) 
interval=1 day 1 753. 2_±30. 1 100. 4 
2 722- 1_±40. 6 96. 3 
3 685. 0_±34. 2 91.3 
4 650. 4_±29. 5 36.7 
i::: 619.3_±37.1 82.6 ~ 
6 579. 1_:!:40. 5 11.2 
7 542.8_±21.4 72.4 
8 514.2_:!:30.8 68.6 
9 486.5_:!:29.2 64.9 
10 452. 9_:!:25 .. 4 60. ,, 
control group* 0 721.5_±40.1 96. 1 
( 10) 
interval=) days 1 750.3_±38.6 100.0 
2 713.3_:!:32.5 95.1 
3 688.4.±38.9 91. 8 
4 650.6_:!:28.6 86.7 
5 617.1_±35.8 32.3 
6 578.6_±42.1 77.1 
7 540.2_±28.5 72.0 
8 511.6_:!:35.1 68.2 
9 486.7_:!:23.4 64.9 
10 451. 8_±29. 6 60.2 
control grcui;* a 636.1_±38.2 84.8 
(3 0) 
interval=5 days 1 747.6±27.1 99.7 
2 715. 4_±29. 8 95.4 
3 680.2.±41.1 90.1 
4 651.0_±37. 1 86.8 
5 622.5_±40.4 83. 0 
6 575. 1_±45. 6 76.7 
7 537. 7±32. 2 71.7 
8 508. 3_±29. 7 67.8 
9 48 9. 1_±35. 4 65. 2 
10 446.2±31.2 59.5 
control group* 0 531. 2.± 27. 4 70.8 
(50) 
* Control grcuf S weie the sample remained frozen for 
the days designated in the parentheses 
Table 17. '.rhe · concentraion of doxorurubicin in frozen plasma 
which experienced different freeaing/thawing cycle~ 
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acceptable storage period, with no thawing permitted, was 
set to be 1 month according to these data from tbe ccntrcl 
groups. Also observed from !able 17 was the more 
significant effect of freezing/thawing cycles than that of 
the time period between cycles. A graph of tbe 
freezing/thawing cycles versus doxorubicin concentration 
could further demonstrate this relationship (Fig. 26). 
This discovery was very important in handling plasma 
samples and implied that a reasonable storage time of a 
month was tolerable as long as the repeated 
freezing/thawings were avoided. Eksborg et al~ suqgested 
that adsorption of doxorubicin onto the precipitates of 
these thawed samples might te the reason for degradation 
(52). Although precipitates did occur in thawed plasma, 
they could be easily disrupted and became homogenized by 
well stirring. 
was the plasma 
The persistent precipitates ever existed 
samples of more than three months cld and 
had experienced at least 5 cycles of freezing/thawing. 
~herefore, reasonably fresh plasma (no more than 3 months 
old) was used in all spiked experiments. 
!herefore, the most suitable storaqe conditions for 
plasma samples is to deep-freeze the samples until assay 
and repeated freezing/thawing should be avoided as much as 
possible. And it would be wise to perform the repeated 
( 
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assays within a week and confine the deep-freeze period to 
no more than 1 month. 
( 
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D. Protein Binding 
1. Direct Ultrafiltration Method 
Direct ultrafiltration ('wash-out') method was first 
performed to determined the appropriate doxorubicin 
concentration in the res€rvior cell that usEd in the 
continuous ultrafiltration. And 5 ~g/ml cf doxorubicin 
turned out to be the minimal detectable conceRtration. 
Since only the unbound drug could pass the Diaflo memtrane, 
the ultrafiltrate thus collected also provided a 
measurement of the fraction of doxorubicin bound tc 
albumin. 
In an ideal membrane, the Diaflo membran€ should be 
non-retainable toward doxorubicin and concentration in the 
ultrafiltrate should be exactly the same as that in the 
filtration cell. But the highly stained Diaflo membrane 
indicated that there was some degree of membrane binding, 
and this binding could be guantified by the concentration 
difference teween the ultrafiltrate and the filtration cell 
solution in the blank run. lhe concentration difference 
between ultrafiltrate and the filtration cell sclution of d 
normal run (with 4 % albumin in the filtration 
cell),conseguently represented not only the fraction tound 
to albumin but also the fraction bound tc memtrane. 
consequently decreased the 
doxorubicin binding ( 6 7) • 
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available surface area for 
1hus, a competitive tinding 
toward the Diaflo memtrane was observed between doxorubicin 
and albumin. The memtrane binding fhenomenon usually could 
be lessened by increasing doxorubicin concentration in the 
filtraticn cell. Experiments were carried out with higher 
concentration (upto 20 Mg/ml) but no significant 
improvement was detected. 1berefore, no information 
regarding the fraction bound of doxorubicin was availatle 
from this direct ultrafiltration method. And this unusual 
result imflied that doxorubicin may not be highly bound to 
albumin otherwise, the effect of memtrane binding would 
have been insignificant. 
2. The Continuous Ultrafiltration Method 
Ultrafiltrates of a •wash-in' (continuous) experiment 
were collected and assayed Chromatographically. Small 
fractions of ultrafiltrate (0.5-1.0 ml) were collected for 
the first 15 ml and ultrafiltration was stopped after the 
collection of about 40 ml of ultrafiltrate. A blank run 
with no albumin in the filtration cell was performed to 
correct for mem~rane tinding cf doxorubicin. 
For an .ideal membrane, i.e., the dialyzatle species 
penetrates unretarded through the memtrane and does not 
( 
I 
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bind to the membrane (67), the following expres~ion holjs 
true in this case: 
c V - V' 
1 n ( -=c __ r___,c=---
r - f 
Cr: the concentration 
Cf: the concentration 
of drug 
of drug 
v . the cumulative volume of . 
v': the api;arent void volume 
Vo: the average sample volume 
during the run 
( 2. 1 ) 
in reservoir cell 
in ultrafiltrate 
ultrafiltrate 
of the system 
in the filtration cell 
lhis relationship shows that a plot of ln(Cr/{Cr-Cf)) 
versus V should be a straight line with slc~e egual to 1/V0 
and an intercept of ln{Cr/(Cr-Cf)). Representative plots 
are shown in Fig 27. Although the above equation bolds 
true for either a blank or normal run, the apparent void 
volume (V') and the sample volume of the filtration cell 
(V 0 ) could be tetter estimated from the tlank run since 
less interference existed. 
The sauple vclume of the filtration cell ( v 0 ) , 
calculated from the slo~e {slope=1/V0 ) of the the blank run 
in this group, was 97.9 ml. This value was much higher 
( 
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than the observed value of 8 ml. Therefore, memtrane 
binding was significant for doxorubicin. This mem.l:rane 
binding proFerty could also be observed from the large 
apparent void volume (V 1 =17.0 ml) and the large area 
between sigmoid curves of the blank run and of the normal 
run. For doxoruticin, Diaflo membrane did not .l:ehave 
ideally and did retain doxoru.l:icin to some degree, i.e., 
the reflection coefficient (~) was not equal to zero. 1he 
reflection coefficient is defined as follows (67): 
( 2. 2) 
where c• is the free drug concentration in the filtration 
cell and Cf is the drug concentration in the ultrafiltrate. 
Accordingly, equation 
ln 
c 
r 
(2.1) should te modified as follows: 
( 2 . J ) 
~he slope of the straight line from a blank run should 
then be (1-(J")/Vo- ~he reflection coefficient thus 
calculated, taking ~ as the observed value of 8 ml, was 
0.918. This value was much higher than those of Blatt §1 
al., which ranging from 0.1-0.25 (67). 1herefore, effort 
was made to decrease this mem.l:rane binding phencmenon. 
\ 
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Correction for memtrane binding can te made, as 
suggested by Blatt et al., by either an increase in ratio 
of the sam~le volume (i.e., the volume of filtration cell) 
to memtrane area or by an increase in the concentration of 
reservoir cell (67). Due to the fixed ratio of the sample 
cell and membrane area in the ultrafiltration unit, 
increment in doxorubicin concentration was made to decrease 
memtrane binding. Higher concentrations of doxorubicin 
were prepared for the reservoir cell and the results showed 
in Fig. 28. From Fig. 28, the apparent void volume of the 
system were 12.20 ml, 21.08 ml, 22.91 ml respectively for 
reservoir concentration of 20, 10, 5 ~g/ml. The reflection 
coefficient did decrease to 0.511 when reservoir 
concentration of do:xor ubici.n was 20 AAg/ml. Ibis 
concentration of 20 ~g/ml, however, was beyound the normal 
physiological range of doxorubicin (1 - 10 ~g/ml) and it 
would be meaningless to perform such a study 
(15,44,45,79-81). 
Three repeated runs of 10 ug/ml were ·perfcrrred and the 
Scatcbard ~lots of these data showed in Fiq. 29. It was 
observed from these plots that there were more· than one 
binding sites in albumin for doxorubicin. 'Iheref ore, the 
following eguation would be adequate to express this type 
of tinding(58,62) 
n 
r =L N . l i=l 
( 2 . 4) 
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Figure 28 . Ultrafi ltrat i on of doxorub icin through the Diaflo PM-1 0 
membrane for various concentrations at 10 p.s .i .. 
Data were obtained from blank runs (albumin - U) of 5 , 10 
and 20 Mg/ml of doxorubicin solutions . 
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For doxorubicin, Ni, Ki should be the same for a fixed 
concentration of albumin. This was not the case in the 
curvilinear plots shown in Fig. 29. 
The variation may result from the binding variation 
among the Diaflo memtranes used. A protein binding study 
of methyl orange was performed under the same conditions. 
ihe Scatchard plots of these data showed in Fig. 30. lhe 
tinding patterns changed, i.e., with different Ni 
only when the concentration of altumin differed. 
and Ki, 
Cata of 
the same albumin concentration superimposed with each other 
regardless of the concentration of metnyl orange. The 
reflection coefficient and void volume were 0.022 and 1.2 
ml for curve A (0.1 ~ altumin solution) and 0.521 and 1.4 
ml for curve B (0.2 % albumin solution). And it was 
confirmed that the much larger void volume of the 
doxorubicin data was resulted from the delayed elution of 
doxorubicin caused by membrane binding. And the higher 
values in the reflection coefficient in doxoruticin tinding 
study was also attrituted to memtrane binding. 
In sumary, continuous ultrafiltration proved to te an 
inadequate method for studying the protein tinding of 
doxorubicin. The Diaflo memtrane showed such a large 
·degree of binding toward doxoruticin that caused an 
inconsistancy among data. And the higher doxoruticin 
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concentration that would have eliminated sucb phenomenon 
(20 ~g/ml) was vay beyound the rage of doxorubicin levels 
in plasma samples (15,44,45,79-81). 
The major obstacle of studying doxorubicin protein 
binding, therfore, was the binding to Diaflo memtrane in 
the ultrafiltration method. A similar observation was made 
by Barris and Gross when a dialysis method was attempted to 
interpret doxorubicin protein binding (63). The 
curvilinear behavior on the Scatchard plot was difficult to 
interpret due tc the binding of doxorubicin to cellulose 
dialysis bag. However, an ultracentrifugation method of 18 
hours was performed and an extent of 50 % doxoruticin bound 
to hu•an plasma was determined. Chan ~ al. re-analyzed 
the original Scatchard plot data of Barris and Gross and 
determined that the fraction bound in the therapeutic 
plasma concentration range was 0.9 rather than the orginal 
reported 0.5 (64). They did not offer specific reasons for 
such a modificaiton and the resultant data of 0.9 fraction 
bound was, therefore, not convincing. And 
ultracentrifugation seemed to be the last resort for the 
determination of the fraction bound of doxorubicin to 
albumin solution. 
( 
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3. lbe Ultracentrifugation Method 
The results from the ultracentrifugation method showed 
that 70.5±2-4 % of doxorubicin was bound to 4 ~ altumin. 
This value was obtained after the correction for 
non-specific adsorption of 3.6 % was made. 
Although this result was obtained ty covering only one 
concentration of doxorubicin solution it provided an 
initial estimation of the protein tinding of dcxorubicin. 
Thus, doxcrubicin was not highly tound to altumin. And 
plasma levels or even tissue levels would not likely te 
influenced ty changes of protein binding. lherefore, the 
possible role of plasma doxorubicin serving as a depot was 
excluded frcm this otservation. 
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IV. CONCIUSICNS 
1. The Sep-pak method was coupled with the reversed phase 
liquid chromatography and thus provided 
efficient reproducible and simple assay 
doxoruticin and its metatolites. 
a seusitive, 
method for 
2. The Sep-pak method recovered 107.3 % of the spiked 
amount from plasma and 97.8 % from tissue sanfles. 
~- Plasma samples required no preliminary treatment while 
tissue samples needed to te homogenized and freed from 
tinding cf doxcrubicin to nuclear components ty silver 
nitrate. 
4. 1he Sep-pak method was superior to the conventional 
extraction method in efficiency (107.3 % vs. 8c.1 ~), 
Frocessing time (1 minute vs. 30 minutes fer samfle), 
and ease of operation (one single procedure vs. three 
extractions). 
5. 1he HPLC system consisted of a chromatographic column, a 
solvent delivery system, a fluorescence detector, a SC 
( 
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102 active filter, an automatic sample processor and a 
data acquisition system. And various modes of HPLC, 
different in the column and mobile phase used, were 
under investigation. The HPLC system that em~loyed a 
C-18 column and a mobile phase cf 0.01 M H3 FO+ in 40 ~ 
acetonitrile sclution was good for stability studies of 
doxorubicin. ~he retention times cf doxoruticin and 
daunorubicin were 3.93 and 5.34 minutes respectively, 
which provided a good resolution tetween these two 
compounds and saved the time and solvents cf analysis. 
The HPLC system that used a C-18 column and a mobile 
phase of 0.01 ! H3 EC+ in 35 3 acetonitrile solution was 
good for protein binding studies. This system provided 
a good resolution between interferences and doxorubicin 
and a short retention time (5.70 minutes for 
doiorubicin) to be economic of time and solvent of 
analysis. The HPlC system that used a C-18 cclumn and a 
mobile phase of a mixture of 0.01 M NH4 H~FO+ solution 
and methanol (40:60) was used for the analysis of 
doxorubicin and its metabolites in biological samples. 
It provided a good resoluticn among doxcrubicin and its 
metabolites, however, 68.02 ~ of 
simultaneously lost. A normal phase 
studied and offered no advantages 
menticned above. 
sensitivity was 
HfLC system was 
over tbe systems 
( 
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6. Pharmacokinetics of do~orubicin and its metabolites, 
using the developed assay method, were studiEd in human 
and rat .flasma, and rat kidneys. The concentrations of 
doxorubicin have teen demonstrated to te in good 
agreement witn those 0£ the literature and have a small 
variation in refeated assays. Pharmacokinetic 
parameters, such as initial ccncentraticn, volume of 
distribution, half-lives and microconstants (K,.2 , K.z.1 
and K£L), were obtained by AUTOAN and they showed good 
agreement with each other, particular in human plasma 
samples. The half-lives of~ and ~ phases correlated 
well with literature data. However, a ccmfarison of the 
pharmacokinetic parameters tetween the young and cld 
rats failed tc demonstrate significant effects of agE on 
doxoruticin pharmacokinetics. These studies did 
of coupli11Q of 
HPLC system. 
demonstrate the successful application 
the Sep-~ak method and the reversed phase 
7. Doxorubicin was more stable in acidic mEdia. .In a 
buff er system of 
stabilit~ dropped 
citrate-phosphate-borate 
drastically around pH 
l:uffEr, its 
11. The 
stability of doxoruticin was also influEnced ty tn~ 
tufferin~ agents 
constants may be 
same pH. 
used and 
20-f old 
the 
in 
di.f ference rate 
different tufters of the 
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8. The recommanded storage conditions for doxorubicin in 
( 
plasma was to deep-freeze the samples until analysis and 
the repeated thawing/freezing should be avoided as much 
as possible. Plasma samples remained statle (i.e., 
degraded nc more than 15 % of original doxorubicin) 
.,.. 
within one month and the length of the time inteLvals 
l:etween thawings had no significant ef fect!S on 
doxorubicin degradati0n. 
9. Dltrafiltration was found to te unsuitatle for the 
protein binding study o.f doxorul:::icin. '.Ille hig.b degree 
of membrane binding hindered the observation cf fraction 
bound by the direct method and caused inconsistant data 
( in the continuous method. Eut the ultracentrifugatior. 
methcd revealed that 0.7 fraction of doxoru.ticin was 
bound t9 plasma solution (4 3 altumin in ~B 7.4 
phosphatE tuffer) • 
.. 
. Future Studies 
SEveral fOssibilities for future investigation have 
resulted from this work: 
1. The stability of ddxorubici~ in tissue samples should be 
investigated. The sttitable storage conditions for 
( 
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tissue samples could be established only a£tEr the 
maximal storage period and the effects of 
thawing/freezing cycles on degradation have been 
determined. 
2. -The fraction bound of doxorubicin to albumin should te 
determined by the ultracentrifugation methcd witb more 
than one concentra~ions in the phsiological range. 
These experiments will buffer the possible variation in 
the fraction tound caused by difference in doxorubicin 
concentrations and. therefore. provides a mere accurate 
data. Besides, it would be advantageous to obtain a 
series data of - molar _ratios at dif fe.rent free 
concentrations of doxorubicin and thus the lliOrE 
important binding Farameters, such as the number of 
independent binding sites, the number 0£ doxorubicin 
molecules binds to each site and the association 
con~tants, could then be determined. 
3. A complete pharmacokinetic profile of doxoruticin in 
rats should te established by assaying the levels of 
doxcruticin and its metabolites in plasma. liver,-
kidney, spleen, lung and heart. After a detailed 
understanding of the kinetics of distri.tution and 
elimination of doxorubicin, a suitatle pharmacokinetic 
model could then ( De established. Ey this 
( 
( 
1 4 1 
pharmacokinetic model, monitors of cardiac toxicities 
could be possibly established and suitable dose and 
schedule of administration can te determined to reach 
the predicted drug concentrations in plasma and tissues 
on an individual tasis. 
4. Larger sample size (n>3J 0£ rats of young, m~dium and 
old age should be included in the study of the effects 
of age on ~oxorubicin pharmacokinetics. Since there is 
an increasing proportion of the aged in total patient 
population, this pbarmacokin~tic study in geriatrics may 
provide tetter means to dete~mine the dose and schedule 
of admininstration of doxoruhicin. 
( 
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AFPENDII 
sample• injection peak height coefficient 
(DOI/DAO) volume ratio . cf variation 
(ng/111) (A.Al) 
20/100 200 
,,-
0.1353,!0.0059 
40/100 200 0.2458.:!:0.0262 
60/100 200 0.5010.:!:0.0085 
100/100 200 0.6341.:!:0-1000 
150/100 200 0.8950.:!:0.0167 
200/400 100 1.2927.:!:0.0722 
300/400 100 0.1803.:!:0-0113 
400/400 100 1.9282+0.5233 
500/400 50 3. 0074,!0. 3020 
600/400 50 3.2724.:!:0-1593 
800/400 ,. 50 4.3371,!0.1067 
1000/400 50 5.0563,!0.1565 
1200/400 25 7.0102.:!:0.1808 
1600/400 25 8.8926.:!:0.1562 
2000/400 25 9.7910.±0.3743 
* The samples are ex~ressed as the concentration of 
doxorubicin (DOI) and daunorubicin (DAU) in ng/ml 
4.34 
10. 66 
1.69 
15. 77 
1.86 
o. 94 
0.61 
2. 71 
10.04 
4. 87 
2. 46 
3.09 
2.58 
1.76 
3.86 
Table 1. The peak height ratios of the standard curve of spiked 
plasma samples by organic extraction method. The BPlC system 
consisted of a C-18 column, a motile phase of 0.01 ~ H!EO~ in 
32 ~ acetonitrile and a flow rate of 1.0 ml/min 
( 
sample• injection peak height 
(DOX:-DAO) vo.lume ratio 
(ng/ml) (Lt!) 
10-200 200 0.1617+0.0132 
30-200 200 o.4613+0.0438 
50-200 200 0.7497,!0.0380 
75-200 100 1.1253,!0.0195 
100-200 100 1.5525,!0.0252 
200-200 50 2. 6621.:!:0. 06 79 
300-200 50 4.7691.:!:0-2572 
' 400-800 40 6.4345+0.2454 
500-800 25 7. 1413,!0. 0794 
600-800 25 8.8011,!0.1483 
700-800 25 9.5400,!0.0400 
800-800 10 11.1401,!0.1547 
900-800 10 12.0020,!0. 4290 
1000-800 10 13.6960,!0. 7998 
• The samp.les are expressed as the concentration of 
doxorubicin {DOI) and daunorubicin (DAU) in ng/ml 
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coefficient 
of variation 
8.20 
9.50 
5.07 
1.74 
1.63 
2.55 
5.39 
3.81 
1.11 
1.68 
0.42 
1.39 
3.57 
5.84 
Table 2. The peak height ratios of the standard curve of spiked 
plasma samples by Sep-pak method. The HPLC system consisted of a 
C-18 co.lum.n, a mobile phase of 0.01 ! BjP04 in 32 ' acetonitrile 
and a flow rate of 1.0 m.l/min • 
...... ~ -"""'-· --~ _,,,_ ___ _ ______ _..,. _____ .. _ ·- --·------·~ ·- --- - - ~- --· ------ -· - .. -· ---~ - -----~--- - __ p _____ - -
( 
sample* injection peak height coefficient 
(DOX-DAU) volume ~atio of variation 
(nq /Sall ple) (.&.&l) 
50-800 100 o. 2308,:!:0. 0057 2.46 
100-800 100 0.4446,!0.0205 4.62 
200-800 100 0.7579,!0.0172 2. 26 
400-800 75 1.3191±0.0612 4.64 
600-800 75 1.1729±0-0408 :t. 36 
800-800 50 2.3547+0.7794 7.62 
1000-800 50 2.5961,:!:0.0998 3.84 
1200-800 40 3.3504,:!:0.1051 3.14 
\ 
1400-800 30 4.7392±0-1543 3. 26 
1600-800 30 5.1763±0-2663 5.14 
1800-800 25 5.9337±0-3815 6.43 
2000-800 25 7.4022±0.6456 8.72 
• The samples are expressed as the concentration of 
doxorubicin (DOX) and daunorubicin (DAU,) in ng/sample. 
Since the final sample volume was apFroximate 1 ml, 
this expression was similar to that used for the 
the plasma samples. 
-
Table 3. The peak height ratios of the standard curve of spiked 
liver samples by Sep-pak method. The BPLC system sonsisted of a 
C-18 coluJUl, a mobile phase of 0.01 ! IB4H~20 4 solution and 
methanol (40:60) and a flow rate of 1.0 ml/min. 
( 
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sami:le• injection peak height coefficient 
(DOI-DAO) volume ratio of variation 
(ng/sa.11ple) (~l) 
30-1000 120 0.0627+0.0060 9.54 
100-1000 100 0.1666..:!:0.0106 E.39 
200-1000 100 o.q300+0.012a 2.96 
400-1000 100 0.7896..:!:0-0169 2.14 
800-1000 50 1. 2831..:!:0-0159 1.24 
1200-1000 30 1.8715.±0.0376 2. 01 
1600-1000 20 2. 4533..:!:0-1242 5.06 
2000-1000 20 3.1644+0.0518 1.64 
-
2400-1000 14 0 3. 7609.;!:0.0912 2.43 
2800-1000 14 4.8768+0.2053 4.21 
* The samples are expressed as the concentration of 
doxorubicin (DOX) and daunorubicin (DAU) in ng/sample. 
' 
Table 4. The peak height ratios of the standard . curve of spiked . 
kidney samples by Sep-pak method. The BPLC system consisted of a 
C-18 coluan, a mobile phase of 0.01 ft BH+HaEOt solution and 
methanol (40:60) and a flow rate 0£ 1.0 ml/min. 
·~~_..,~__. _._ ..... .. ..-...- ------- ·-- -- .. ---~..-----·---- -·------~---- .. ~ -·--------------- --·-----·-··- -
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